<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>POMALYST- pomalidomideÂ capsuleÂ </strong><br>Celgene Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use POMALYST safely and effectively.  See full prescribing information for POMALYST.<br><br>POMALYST<span class="Sup">Â®</span> (pomalidomide) capsules, for oral use<br>Initial U.S. Approval:  2013</span></div>
<div class="Warning"><div>
<h1 class="Warning"></h1>
<h1 class="Warning"></h1>
<p class="Highlighta"><span class="Bold">WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">THROMBOEMBOLISM</span></span> </p>
<p class="Highlighta"><span class="Bold Italics">See full prescribing information for complete boxed warning</span> </p>
<p class="Highlighta"><span class="Bold">EMBRYO-FETAL TOXICITY</span> </p>
<ul>
<li><span class="Bold">POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue.  Thalidomide is a known human teratogen that causes severe life-threatening <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>  (<a href="#SB040">4,</a><a href="#SB051"> 5.1,</a><a href="#SB081"> 8.1</a>).</span></li>
<li>
<span class="Bold">For females of reproductive potential: Exclude pregnancy before start of treatment.  Prevent pregnancy during treatment by the use of 2 reliable methods of contraception (<a href="#SB051">5.1,</a><a href="#SB086"> 8.6</a>).</span><br><br>
</li>
</ul>
<p class="Highlighta"><span class="Bold">POMALYST is available only through a restricted program called POMALYST REMS<span class="Sup">Â®</span> (<a href="#SB052">5.2</a>).</span><br><br> </p>
<p class="Highlighta"><span class="Bold">VENOUS AND ARTERIAL <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">THROMBOEMBOLISM</span></span> </p>
<ul><li><span class="Bold">Deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> occur in patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> treated with POMALYST. Antithrombotic prophylaxis is recommended (<a href="#SB053">5.3</a>).</span></li></ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table class="Noautorules"><tbody class="Headless">
<tr valign="bottom">
<td align="left">
<a href="#e1-b86c-0800200c9a66-jybw">Boxed Warning</a>Â Â Â </td>
<td align="left">04/15</td>
</tr>
<tr valign="bottom">
<td align="left">Indications and Usage (<a href="#SB011">1.1</a>)Â Â Â </td>
<td align="left">04/15</td>
</tr>
<tr valign="bottom">
<td align="left">Dosage and Administration (<a href="#SB021">2.1</a>, <a href="#SB022">2.2</a>)Â Â Â </td>
<td align="left">04/15</td>
</tr>
<tr valign="bottom">
<td align="left">Warnings and Precautions (<a href="#SB053">5.3</a>, <a href="#SB054">5.4</a>, <a href="#SB055">5.5</a>, <a href="#SB056">5.6</a>, <a href="#SB057">5.7</a>, <a href="#SB058">5.8</a>)Â Â Â </td>
<td align="left">04/15</td>
</tr>
<tr valign="bottom">
<td align="left">Warnings and Precautions (<a href="#AG510">5.10</a>)Â Â Â </td>
<td align="left">05/14</td>
</tr>
</tbody></table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"></h1>
<h1 class="Warning"></h1>
<p class="Highlighta"><span class="Bold">WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">THROMBOEMBOLISM</span></span> </p>
<p class="Highlighta"><span class="Bold Italics">See full prescribing information for complete boxed warning</span> </p>
<p class="Highlighta"><span class="Bold">EMBRYO-FETAL TOXICITY</span> </p>
<ul>
<li><span class="Bold">POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue.  Thalidomide is a known human teratogen that causes severe life-threatening <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>  (<a href="#SB040">4,</a><a href="#SB051"> 5.1,</a><a href="#SB081"> 8.1</a>).</span></li>
<li>
<span class="Bold">For females of reproductive potential: Exclude pregnancy before start of treatment.  Prevent pregnancy during treatment by the use of 2 reliable methods of contraception (<a href="#SB051">5.1,</a><a href="#SB086"> 8.6</a>).</span><br><br>
</li>
</ul>
<p class="Highlighta"><span class="Bold">POMALYST is available only through a restricted program called POMALYST REMS<span class="Sup">Â®</span> (<a href="#SB052">5.2</a>).</span><br><br> </p>
<p class="Highlighta"><span class="Bold">VENOUS AND ARTERIAL <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">THROMBOEMBOLISM</span></span> </p>
<ul><li><span class="Bold">Deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> occur in patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> treated with POMALYST. Antithrombotic prophylaxis is recommended (<a href="#SB053">5.3</a>).</span></li></ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">POMALYST is a thalidomide analogue indicated, in combination with dexamethasone, for patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy (<a href="#SB011">1.1</a>). </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">4 mg per day taken orally on Days 1-21 of repeated 28-day cycles until disease progression (<a href="#SB021">2.1</a>). Refer to <a href="#SB141">section 14.1</a> for dexamethasone dosing (<a href="#SB141">14.1</a>). </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Capsules: 1 mg, 2 mg, 3 mg, and 4 mg (<a href="#SB030">3</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>
<span class="Bold">Pregnancy</span> (<a href="#SB040">4</a>)</li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Hematologic Toxicity: <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> was the most frequently reported Grade 3/4 adverse event.  Monitor patients for hematologic toxicities, especially <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (<a href="#SB054">5.4</a>).</li>
<li>Hepatotoxicity: <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span> including fatalities; monitor liver function tests monthly (<a href="#SB055">5.5</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and severe dermatologic reactions have been reported. Discontinue POMALYST for <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and severe dermatologic reactions (<a href="#SB056">5.6</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span> (TLS): Monitor patients at risk of TLS (i.e., those with high tumor burden) and take appropriate precautions (<a href="#AG510">5.10</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (â‰¥30%) included <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, upper-<span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (<a href="#SB061">6.1</a>). </p>
<p class="Highlighta">Â Â  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul><li>Strong CYP1A2 Inhibitors: Avoid the use of strong CYP1A2 inhibitors unless medically necessary (<a href="#SB023">2.3</a>, <a href="#SB071">7.1</a>, <a href="#SB123">12.3</a>).</li></ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Nursing Mothers: Discontinue drug or nursing taking into consideration importance of drug to mother (<a href="#SB083">8.3</a>).</li>
<li>Avoid POMALYST in patients with serum creatinine &gt;3.0 mg/dL (<a href="#SB087">8.7</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 4/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="XmChange">WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">THROMBOEMBOLISM</span></span></a></h1>
<h1><a href="#section-1" class="toc">1		INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	<span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span></a></h2>
<h1><a href="#section-2" class="toc">2		DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	<span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Dose Adjustments for Toxicities</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Dose Adjustment for Strong CYP1A2 Inhibitors in the Presence of Strong CYP3A4 and P-gp Inhibitors</a></h2>
<h1><a href="#section-3" class="toc">3		DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4		CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">Pregnancy</a></h2>
<h1><a href="#section-5" class="toc">5		WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Embryo-Fetal Toxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	POMALYST REMS Program</a></h2>
<h2><a href="#section-5.3" class="toc"><span class="XmChange">5.3	Venous and Arterial <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span></span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="XmChange">5.4	Hematologic Toxicity</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="XmChange">5.5 Hepatotoxicity</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> </a></h2>
<h2><a href="#section-5.7" class="toc"><span class="XmChange">5.7	<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional State</span></span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="XmChange">5.8	<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9	Risk of Second Primary Malignancies</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span></a></h2>
<h1><a href="#section-6" class="toc">6		ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7		DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Drugs That May Increase Pomalidomide Plasma Concentrations</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Drugs That May Decrease Pomalidomide Plasma Concentrations</a></h2>
<h1><a href="#section-8" class="toc">8		USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5	Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	Females of Reproductive Potential and Males</a></h2>
<h2><a href="#section-8.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14	CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	<span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span></a></h2>
<h1><a href="#section-14" class="toc">15	REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1	How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2	Storage</a></h2>
<h2><a href="#section-15.3" class="toc">16.3	Handling and Disposal</a></h2>
<h1><a href="#section-16" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="e1-b86c-0800200c9a66-jybw"></a><a name="section-1"></a><p></p>
<h1 style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange">WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">THROMBOEMBOLISM</span></span></h1>
<p class="First" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Embryo-Fetal Toxicity</span></span></p>
<ul>
<li style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue.  Thalidomide is a known human teratogen that causes severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> or embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>.  In females of reproductive potential, obtain 2 <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy tests</span> before starting POMALYST treatment.</span></span></li>
<li style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after stopping POMALYST treatment [see <span class="Italics">Contraindications (<a href="#SB040">4</a>), Warnings and Precautions (<a href="#SB051">5.1</a>),</span> and <span class="Italics">Use in Specific Populations (<a href="#SB081">8.1,</a><a href="#SB086"> 8.6</a>)</span>].</span></span></li>
</ul>
<p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">POMALYST is only available through a restricted distribution program called POMALYST REMS [see<span class="Italics"> Warnings and Precautions (<a href="#SB052">5.2</a>)</span>].</span></span></p>
<p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Venous and Arterial <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span></span></span></p>
<ul><li style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> occur in patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> treated with POMALYST. <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> antithrombotic measures were employed in clinical trials. Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient's underlying risk factors  [see<span class="Italics"> Warnings and Precautions (<a href="#SB053">5.3</a>)</span>].</span></span></li></ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="SB010"></a><a name="section-1"></a><p></p>
<h1>1		INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SB011"></a><a name="section-1.1"></a><p></p>
<h2>1.1	<span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">POMALYST, in combination with dexamethasone, is indicated for patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="SB020"></a><a name="section-2"></a><p></p>
<h1>2		DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SB021"></a><a name="section-2.1"></a><p></p>
<h2>2.1	<span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span></h2>
<p class="First">Females of reproductive potential must have negative pregnancy testing and use contraception methods before initiating POMALYST [see<span class="Italics"> Warnings and Precautions (<a href="#SB051">5.1</a>)</span> and <span class="Italics">Use in Specific Populations (<a href="#SB086">8.6</a>)</span>].</p>
<p style="border-left:1px solid;"><span class="XmChange">The recommended starting dose of POMALYST is 4 mg once daily orally on Days 1-21 of repeated 28-day cycles until disease progression.  POMALYST should be given in combination with dexamethasone [see<span class="Italics"> Clinical Studies (<a href="#SB141">14.1</a>)</span>].</span></p>
<p>POMALYST may be taken with water.  Inform patients not to break, chew, or open the capsules.  POMALYST should be taken without food (at least 2 hours before or 2 hours after a meal).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB022"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Dose Adjustments for Toxicities</h2>
<table width="700">
<caption><span>Table 1:	Dose Modification Instructions for POMALYST for Hematologic Toxicities</span></caption>
<tfoot><tr class="First Last"><td colspan="2">ANC, absolute neutrophil count</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule"><span class="Bold">Â Â Toxicity</span></td>
<td class="Botrule Rrule"><span class="Bold">Â Â Dose Modification</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â Â <span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span><ul>
<li>ANC &lt;500 per mcL or <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> more than or equal to 38.5Â°C and ANC &lt;1,000 per mcL)<br><br>
</li>
<li>ANC return to more than or equal to 500 per mcL</li>
</ul>
</td>
<td class="Botrule Rrule" valign="top">
<br><ul>
<li>Interrupt POMALYST treatment, follow CBC weekly<br><br>
</li>
<li>Resume POMALYST treatment at 3 mg daily</li>
</ul>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><ul>
<li>For each subsequent drop &lt;500 per mcL<br><br>
</li>
<li>Return to more than or equal to 500 per mcL</li>
</ul></td>
<td class="Botrule Rrule" valign="top"><ul>
<li>Interrupt POMALYST treatment<br><br>
</li>
<li>Resume POMALYST treatment at 1 mg less than the previous dose</li>
</ul></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â Â <span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span><ul>
<li>Platelets &lt;25,000 per mcL<br><br>
</li>
<li>Platelets return to &gt;50,000 per mcL</li>
</ul>
</td>
<td class="Botrule Rrule" valign="top">
<br><ul>
<li>Interrupt POMALYST treatment, follow CBC weekly<br><br>
</li>
<li>Resume POMALYST treatment at 3 mg daily</li>
</ul>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><ul>
<li>For each subsequent drop &lt;25,000 per mcL<br><br>
</li>
<li>Return to more than or equal to 50,000 per mcL</li>
</ul></td>
<td class="Botrule Rrule" valign="top"><ul>
<li>Interrupt POMALYST treatment<br><br>
</li>
<li>Resume POMALYST treatment at 1 mg less than previous dose</li>
</ul></td>
</tr>
</tbody>
</table>
<p class="First" style="border-left:1px solid;"><span class="XmChange">To initiate a new cycle of POMALYST, the neutrophil count must be at least 500 per mcL and the platelet count must be at least 50,000 per mcL. If toxicities occur after dose reductions to 1 mg, then discontinue POMALYST.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Permanently discontinue POMALYST for <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">skin exfoliation</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">bullae</span>, or any other severe dermatologic reaction [see<span class="Italics"> Warnings and Precautions (<a href="#SB056">5.6</a>)</span>].</span></p>
<p style="border-left:1px solid;"><span class="XmChange">For other Grade 3 or 4 toxicities, hold treatment and restart treatment at 1 mg less than the previous dose when toxicity has resolved to less than or equal to Grade 2 at the physicianâ€™s discretion.  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB023"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Dose Adjustment for Strong CYP1A2 Inhibitors in the Presence of Strong CYP3A4 and P-gp Inhibitors</h2>
<p class="First">Avoid co-administration of strong inhibitors of CYP1A2. If necessary to co-administer strong inhibitors of CYP1A2 in the presence of strong inhibitors of CYP3A4 and P-gp, reduce POMALYST dose by 50%. No clinical efficacy or safety data exist [see<span class="Italics"> Drug Interactions (<a href="#SB071">7.1</a>) and Clinical Pharmacology (<a href="#SB123">12.3</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="SB030"></a><a name="section-3"></a><p></p>
<h1>3		DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">POMALYST is available in the following capsule strengths:</p>
<p>1 mg: Dark blue opaque cap and yellow opaque body, imprinted â€œPOMLâ€? on the cap in white ink and â€œ1 mgâ€? on the body in black ink
							<br>2 mg: Dark blue opaque cap and orange opaque body, imprinted â€œPOMLâ€? on the cap and â€œ2 mgâ€? on the body in white ink
							<br>3 mg: Dark blue opaque cap and green opaque body, imprinted â€œPOMLâ€? on the cap and â€œ3 mgâ€? on the body in white ink
							<br>4 mg: Dark blue opaque cap and blue opaque body, imprinted â€œPOMLâ€? on the cap and â€œ4 mgâ€? on the body in white ink
						</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="SB040"></a><a name="section-4"></a><p></p>
<h1>4		CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SB041"></a><a name="section-4.1"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">POMALYST can cause fetal harm when administered to a pregnant female [see<span class="Italics"> Warnings and Precautions (<a href="#SB051">5.1</a>)</span> and <span class="Italics">Use in Specific Populations (<a href="#SB081">8.1</a>)</span>]. POMALYST is contraindicated in females who are pregnant. Pomalidomide is a thalidomide analogue and is teratogenic in both rats and rabbits when administered during the period of organogenesis.  If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="SB050"></a><a name="section-5"></a><p></p>
<h1>5		WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SB051"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Embryo-Fetal Toxicity</h2>
<p class="First">POMALYST is a thalidomide analogue and is contraindicated for use during pregnancy.  Thalidomide is a known human teratogen that causes severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> or embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> [see<span class="Italics"> Use in Specific Populations (<a href="#SB081">8.1</a>)</span>].  POMALYST is only available through the POMALYST REMS program [see<span class="Italics"> Warnings and Precautions (<a href="#SB052">5.2</a>)</span>].</p>
<p><span class="Underline">Females of Reproductive Potential</span><br>Females of reproductive potential must avoid pregnancy while taking POMALYST and for at least 4 weeks after completing therapy.</p>
<p>Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy.  </p>
<p>Two <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy tests</span> must be obtained prior to initiating therapy.  The first test should be performed within 10-14 days and the second test within 24 hours prior to prescribing POMALYST therapy and then weekly during the first month, then monthly thereafter in women with regular menstrual cycles, or every 2 weeks in women with <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">irregular menstrual cycles</span> [see<span class="Italics"> Use in Specific Populations (<a href="#SB086">8.6</a>)</span>].</p>
<p><span class="Underline">Males</span><br>Pomalidomide is present in the semen of patients receiving the drug.  Therefore, males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking POMALYST and for up to 28 days after discontinuing POMALYST, even if they have undergone a successful vasectomy.  Male patients taking POMALYST must not donate sperm [see<span class="Italics"> Use in Specific Populations (<a href="#SB086">8.6</a>)</span>].</p>
<p><span class="Underline">Blood Donation</span><br>Patients must not donate blood during treatment with POMALYST and for 1 month following discontinuation of the drug because the blood might be given to a pregnant female patient whose fetus must not be exposed to POMALYST.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB052"></a><a name="section-5.2"></a><p></p>
<h2>5.2	POMALYST REMS Program</h2>
<p class="First">Because of the embryo-fetal risk [see<span class="Italics"> Warnings and Precautions (<a href="#SB051">5.1</a>)</span>], POMALYST is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called â€œ<span class="Bold">POMALYST REMS</span>.â€?  </p>
<p>Required components of the <span class="Bold">POMALYST REMS</span> program include the following:</p>
<ul>
<li>Prescribers must be certified with the <span class="Bold">POMALYST REMS</span> program by enrolling and complying with the REMS requirements.</li>
<li>Patients must sign a Patient-Physician Agreement Form and comply with the REMS requirements. In particular, female patients of reproductive potential who are not pregnant must comply with the pregnancy testing and contraception requirements [see <span class="Italics">Use in Specific Populations (<a href="#SB086">8.6</a>)</span>] and males must comply with contraception requirements [see<span class="Italics"> Use in Specific Populations (<a href="#SB086">8.6</a>)</span>].</li>
<li>Pharmacies must be certified with the <span class="Bold">POMALYST REMS</span> program, must only dispense to patients who are authorized to receive POMALYST, and comply with REMS requirements.</li>
</ul>
<p>Further information about the <span class="Bold">POMALYST REMS</span> program is available at www.CelgeneRiskManagement.com or by telephone at 1-888-423-5436.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB053"></a><a name="section-5.3"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.3	Venous and Arterial <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> (deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>) and arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>) have been observed in patients treated with POMALYST. In Trial 2, where anticoagulant therapies were mandated, <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. Venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> (VTE) occurred in 4.7% of patients treated with POMALYST and Low-dose Dex, and 1.3% of patients treated with high-dose dexamethasone.  Arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> include terms for arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>, ischemic cerebrovascular conditions, and <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>. Arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> occurred in 3.0% of patients treated with POMALYST and Low-dose Dex, and 1.3% of patients treated with high-dose dexamethasone.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Patients with known risk factors, including prior <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, smoking). Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient's underlying risk factors.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB054"></a><a name="section-5.4"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.4	Hematologic Toxicity</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">In trials 1 and 2 in patients who received POMALYST + Low-dose Dex, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> was the most frequently reported Grade 3/4 adverse reaction, followed by <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>. <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> of any grade was reported in 51% of patients in both trials. The rate of Grade 3/4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> was 46%. The rate of <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> was 8%.</span></p>
<p>Monitor patients for hematologic toxicities, especially <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.  Monitor complete blood counts weekly for the first 8 weeks and monthly thereafter.  Patients may require dose interruption and/or modification [see<span class="Italics"> Dosage and Administration (<a href="#SB022">2.2</a>)</span>].  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB055"></a><a name="section-5.5"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.5 Hepatotoxicity</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span>, including fatal cases, has occurred in patients treated with POMALYST. Elevated levels of <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> and bilirubin have also been observed in patients treated with POMALYST. Monitor liver function tests monthly. Stop POMALYST upon elevation of liver enzymes and evaluate. After return to baseline values, treatment at a lower dose may be considered. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB056"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> </h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and severe dermatologic reactions have been reported. Discontinue POMALYST for <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">skin exfoliation</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">bullae</span>, or any other severe dermatologic reactions, and do not resume therapy [see<span class="Italics"> Dosage and Administration (<a href="#SB022">2.2</a>)</span>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB057"></a><a name="section-5.7"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.7	<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional State</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">In trials 1 and 2 in patients who received POMALYST + Low-dose Dex, 14% of patients experienced <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and 7% of patients experienced a <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>; 1% of patients experienced Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and 3% of patients experienced Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>. Instruct patients to avoid situations where <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span> may be a problem and not to take other medications that may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span> without adequate medical advice.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB058"></a><a name="section-5.8"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.8	<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">In trials 1 and 2 in patients who received POMALYST + Low-dose Dex, 18% of patients experienced <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, with approximately 12% of the patients experiencing <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>. Two percent of patients experienced Grade 3 <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> in trial 2. There were no cases of Grade 4 <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> adverse reactions reported in either trial.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB059"></a><a name="section-5.9"></a><p></p>
<h2>5.9	Risk of Second Primary Malignancies</h2>
<p class="First">Cases of acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> have been reported in patients receiving POMALYST as an investigational therapy outside of <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AG510"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span> (TLS) may occur in patients treated with pomalidomide. Patients at risk for TLS are those with high tumor burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="SB060"></a><a name="section-6"></a><p></p>
<h1>6		ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are described in detail in other labeling sections:</p>
<ul>
<li>Fetal Risk [see <span class="Italics"><a href="#e1-b86c-0800200c9a66-jybw">Boxed Warnings</a>, Warnings and Precautions (<a href="#SB051">5.1,</a><a href="#SB052"> 5.2</a>)</span>]</li>
<li>Venous and Arterial <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span> [see <span class="Italics"><a href="#e1-b86c-0800200c9a66-jybw">Boxed Warnings</a>, Warnings and Precautions (<a href="#SB053">5.3</a>)</span>]</li>
<li>Hematologic Toxicity [see<span class="Italics"> Warnings and Precautions (<a href="#SB054">5.4</a>)</span>]</li>
<li>Hepatotoxicity [see <span class="Italics">Warnings and Precautions (<a href="#SB055">5.5</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> [see<span class="Italics"> Warnings and Precautions (<a href="#SB056">5.6</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional State</span> [see<span class="Italics"> Warnings and Precautions (<a href="#SB057">5.7</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span> [see<span class="Italics"> Warnings and Precautions (<a href="#SB058">5.8</a>)</span>]</li>
<li>Risk of Second Primary Malignancies [see<span class="Italics"> Warnings and Precautions (<a href="#SB059">5.9</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span> [see<span class="Italics"> Warnings and Precautions (<a href="#AG510">5.10</a>)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="SB061"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span></span></p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>In Trial 1, data were evaluated from 219 patients (safety population) who received treatment with POMALYST + Low-dose Dex (112 patients) or POMALYST alone (107 patients). Median number of treatment cycles was 5. Sixty-seven percent of patients in the study had a dose interruption of either drug due to adverse reactions. Forty-two percent of patients in the study had a dose reduction of either drug due to adverse reactions. The discontinuation rate due to adverse reactions was 11%.</p>
<p>In Trial 2, data were evaluated from 450 patients (safety population) who received treatment with POMALYST + Low-dose Dex (300 patients) or High-dose Dexamethasone (High-dose Dex) (150 patients). The median number of treatment cycles for the POMALYST + Low-dose Dex arm was 5. In the POMALYST + Low-dose Dex arm, 67% of patients had a dose interruption of POMALYST, the median time to the first dose interruption of POMALYST was 4.1 weeks. Twenty-seven percent of patients had a dose reduction of POMALYST, the median time to the first dose reduction of POMALYST was 4.5 weeks. Eight percent of patients discontinued POMALYST due to adverse reactions.</p>
<p><a href="#Table2">Tables 2</a> and <a href="#Table3"> 3</a> summarize the adverse reactions reported in Trials 1 and 2, respectively. </p>
<a name="Table2"></a><table class="Noautorules" width="750">
<caption><span>Table 2:	 Adverse Reactions in Any POMALYST Treatment Arm in Trial 1*</span></caption>
<col width="30%">
<col width="15%">
<col width="15%">
<col width="15%">
<col width="15%">
<col width="15%">
<tfoot>
<tr><td colspan="3">
<span class="Sup">*</span> Regardless of attribution of relatedness to POMALYST.</td></tr>
<tr><td colspan="6">
<span class="Sup">a</span> POMALYST alone arm includes all patients randomized to the POMALYST alone arm who took study drug; 61 of the 107 patients had dexamethasone added during the treatment period.
											</td></tr>
<tr><td colspan="6">
<span class="Sup">b</span> Serious adverse reactions were reported in at least 2 patients in any POMALYST treatment arm.<br>Data cutoff: 01 March 2013
												
											</td></tr>
</tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">All Adverse Reactions â‰¥10% in<br> Either Arm</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">Grade 3 or 4 â‰¥5% in Either Arm</span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule" align="center"><span class="Bold">System Organ Class/Preferred Term</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold"><br>POMALYST<span class="Sup">a</span><br>(N=107)</span></td>
<td class="Botrule Rrule" align="center"><span class="Bold">POMALYST + <br>Low-dose Dex<br>(N=112)</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold"><br>POMALYST<br>(N=107)</span></td>
<td class="Botrule Rrule" align="center"><span class="Bold">POMALYST + <br>Low-dose Dex<br>(N=112)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Number (%) of patients with at least one adverse reaction</td>
<td class="Botrule Rrule" align="center">107 (100)</td>
<td class="Botrule Rrule" align="center">112 (100)</td>
<td class="Botrule Rrule" align="center">98 (91.6)</td>
<td class="Botrule Rrule" align="center">102 (91.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Blood and lymphatic system disorders</span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">57 (53.3)</td>
<td class="Botrule Rrule" align="center">55 (49.1)</td>
<td class="Botrule Rrule" align="center">51 (47.7)</td>
<td class="Botrule Rrule" align="center">46 (41.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">41 (38.3)</td>
<td class="Botrule Rrule" align="center">47 (42.0)</td>
<td class="Botrule Rrule" align="center">25 (23.4)</td>
<td class="Botrule Rrule" align="center">24 (21.4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">28 (26.2)</td>
<td class="Botrule Rrule" align="center">26 (23.2)</td>
<td class="Botrule Rrule" align="center">24 (22.4)</td>
<td class="Botrule Rrule" align="center">21 (18.8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Botrule Rrule" align="center">14 (13.1)</td>
<td class="Botrule Rrule" align="center">22 (19.6)</td>
<td class="Botrule Rrule" align="center">7 (6.5)</td>
<td class="Botrule Rrule" align="center">11 (9.8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">&lt;10%</td>
<td class="Botrule Rrule" align="center">&lt;10%</td>
<td class="Botrule Rrule" align="center">6 (5.6)</td>
<td class="Botrule Rrule" align="center">3 (2.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span></td>
<td class="Botrule Rrule" align="center">4 (3.7)</td>
<td class="Botrule Rrule" align="center">17 (15.2)</td>
<td class="Botrule Rrule" align="center">2 (1.9)</td>
<td class="Botrule Rrule" align="center"> 8 (7.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">General disorders and administration site conditions</span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">62 (57.9)</td>
<td class="Botrule Rrule" align="center">70 (62.5)</td>
<td class="Botrule Rrule" align="center">13 (12.1)</td>
<td class="Botrule Rrule" align="center">19 (17.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></td>
<td class="Botrule Rrule" align="center">27 (25.2)</td>
<td class="Botrule Rrule" align="center">19 (17.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">25 (23.4)</td>
<td class="Botrule Rrule" align="center">36 (32.1)</td>
<td class="Botrule Rrule" align="center"> &lt;5%</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td class="Botrule Rrule" align="center">11 (10.3)</td>
<td class="Botrule Rrule" align="center">14 (12.5)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">39 (36.4)</td>
<td class="Botrule Rrule" align="center">27 (24.1)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">38 (35.5)</td>
<td class="Botrule Rrule" align="center">41 (36.6)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Rrule" align="center">37 (34.6)</td>
<td class="Botrule Rrule" align="center">40 (35.7)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">15 (14.0)</td>
<td class="Botrule Rrule" align="center">16 (14.3)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">37 (34.6)</td>
<td class="Botrule Rrule" align="center">36 (32.1)</td>
<td class="Botrule Rrule" align="center">15 (14.0)</td>
<td class="Botrule Rrule" align="center">11 (9.8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4092930" conceptname="Musculoskeletal chest pain">Musculoskeletal chest pain</span></td>
<td class="Botrule Rrule" align="center">25 (23.4)</td>
<td class="Botrule Rrule" align="center">22 (19.6)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></td>
<td class="Botrule Rrule" align="center">23 (21.5)</td>
<td class="Botrule Rrule" align="center">22 (19.6)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Botrule Rrule" align="center">18 (16.8)</td>
<td class="Botrule Rrule" align="center">17 (15.2)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscular weakness</span></td>
<td class="Botrule Rrule" align="center">15 (14.0)</td>
<td class="Botrule Rrule" align="center">15 (13.4)</td>
<td class="Botrule Rrule" align="center">6 (5.6)</td>
<td class="Botrule Rrule" align="center">4 (3.6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone pain</span></td>
<td class="Botrule Rrule" align="center">13 (12.1)</td>
<td class="Botrule Rrule" align="center">8 (7.1)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></td>
<td class="Botrule Rrule" align="center">13 (12.1)</td>
<td class="Botrule Rrule" align="center">19 (17.0)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Botrule Rrule" align="center">8 (7.5)</td>
<td class="Botrule Rrule" align="center">16 (14.3)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Botrule Rrule" align="center">40 (37.4)</td>
<td class="Botrule Rrule" align="center">32 (28.6)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">30 (28.0)</td>
<td class="Botrule Rrule" align="center">38 (33.9)</td>
<td class="Botrule Rrule" align="center">21 (19.6)</td>
<td class="Botrule Rrule" align="center">32 (28.6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">11 (10.3)</td>
<td class="Botrule Rrule" align="center">19 (17.0)</td>
<td class="Botrule Rrule" align="center"> 2 (1.9)</td>
<td class="Botrule Rrule" align="center">10 (8.9)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">&lt;10%</td>
<td class="Botrule Rrule" align="center">&lt;10%</td>
<td class="Botrule Rrule" align="center"> 6 (5.6)</td>
<td class="Botrule Rrule" align="center">5 (4.5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Metabolism and nutrition disorders</span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Botrule Rrule" align="center">25 (23.4)</td>
<td class="Botrule Rrule" align="center">21 (18.8)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">23 (21.5)</td>
<td class="Botrule Rrule" align="center">13 (11.6)</td>
<td class="Botrule Rrule" align="center">11 (10.3)</td>
<td class="Botrule Rrule" align="center">1 (0.9)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td class="Botrule Rrule" align="center">13 (12.1)</td>
<td class="Botrule Rrule" align="center">13 (11.6)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></td>
<td class="Botrule Rrule" align="center">12 (11.2)</td>
<td class="Botrule Rrule" align="center">17 (15.2)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></td>
<td class="Botrule Rrule" align="center">12 (11.2)</td>
<td class="Botrule Rrule" align="center">14 (12.5)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">&lt;10%</td>
<td class="Botrule Rrule" align="center">&lt;10%</td>
<td class="Botrule Rrule" align="center">5 (4.7)</td>
<td class="Botrule Rrule" align="center">6 (5.4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></td>
<td class="Botrule Rrule" align="center">6 (5.6)</td>
<td class="Botrule Rrule" align="center">13 (11.6)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">38 (35.5)</td>
<td class="Botrule Rrule" align="center">50 (44.6)</td>
<td class="Botrule Rrule" align="center">8 (7.5)</td>
<td class="Botrule Rrule" align="center">14 (12.5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Botrule Rrule" align="center">18 (16.8)</td>
<td class="Botrule Rrule" align="center">25 (22.3)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Botrule Rrule" align="center">18 (16.8)</td>
<td class="Botrule Rrule" align="center">12 (10.7)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">Productive cough</span></td>
<td class="Botrule Rrule" align="center">10 (9.3)</td>
<td class="Botrule Rrule" align="center">14 (12.5)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â Oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Botrule Rrule" align="center">6 (5.6)</td>
<td class="Botrule Rrule" align="center">12 (10.7)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center">24 (22.4)</td>
<td class="Botrule Rrule" align="center">20 (17.9)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span></td>
<td class="Botrule Rrule" align="center">23 (21.5)</td>
<td class="Botrule Rrule" align="center">20 (17.9)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Rrule" align="center">16 (15.0)</td>
<td class="Botrule Rrule" align="center">15 (13.4)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Botrule Rrule" align="center">11 (10.3)</td>
<td class="Botrule Rrule" align="center">15 (13.4)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Skin and subcutaneous tissue disorders</span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule Rrule" align="center">22 (20.6)</td>
<td class="Botrule Rrule" align="center">18 (16.1)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">&lt;5%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Botrule Rrule" align="center">16 (15.0)</td>
<td class="Botrule Rrule" align="center">10 (8.9)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></td>
<td class="Botrule Rrule" align="center">10 (9.3)</td>
<td class="Botrule Rrule" align="center">12 (10.7)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></td>
<td class="Botrule Rrule" align="center">8 (7.5)</td>
<td class="Botrule Rrule" align="center">18 (16.1)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">Night sweats</span></td>
<td class="Botrule Rrule" align="center">5 (4.7)</td>
<td class="Botrule Rrule" align="center">14 (12.5)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Investigations</span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â Blood creatinine increased <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">20 (18.7)</td>
<td class="Botrule Rrule" align="center">11 (9.8)</td>
<td class="Botrule Rrule" align="center">6 (5.6)</td>
<td class="Botrule Rrule" align="center">3 (2.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decreased</span></td>
<td class="Botrule Rrule" align="center">16 (15.0)</td>
<td class="Botrule Rrule" align="center">10 (8.9)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increased</span> </td>
<td class="Botrule Rrule" align="center">1 (0.9)</td>
<td class="Botrule Rrule" align="center">12 (10.7)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Psychiatric disorders</span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Botrule Rrule" align="center">14 (13.1)</td>
<td class="Botrule Rrule" align="center">8 (7.1)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional state</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">13 (12.1)</td>
<td class="Botrule Rrule" align="center">15 (13.4)</td>
<td class="Botrule Rrule" align="center">6 (5.6)</td>
<td class="Botrule Rrule" align="center">3 (2.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Botrule Rrule" align="center">7 (6.5)</td>
<td class="Botrule Rrule" align="center">18 (16.1)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Renal and urinary disorders</span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">16 (15.0)</td>
<td class="Botrule Rrule" align="center">11 (9.8)</td>
<td class="Botrule Rrule" align="center">9 (8.4)</td>
<td class="Botrule Rrule" align="center">8 (7.1)</td>
</tr>
</tbody>
</table>
<a name="Table3"></a><table class="Noautorules" width="850">
<caption><span>Table 3:	Adverse Reactions in Trial 2</span></caption>
<col width="32%">
<col width="15%">
<col width="15%">
<col width="15%">
<col width="15%">
<tfoot>
<tr><td colspan="6">
<span class="Sup">a</span> Percentage did not meet the criteria to be considered as an adverse reaction for POMALYST for that category of event (i.e., all adverse events or Grade 3 or 4 adverse events).
											</td></tr>
<tr><td colspan="6">
<span class="Sup">b</span> Serious adverse reactions were reported in at least 3 patients in the POM + Low-dose Dex arm, AND at least 1% higher than the High-dose-Dex arm percentage.<br>Data cutoff: 01 March 2013
												
											</td></tr>
</tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">All Adverse Reactions<br>(â‰¥5% in POMALYST + Low-dose<br> Dex arm, and at least 2% point<br> higher than the High-dose-Dex arm)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">Grade 3 or 4<br>(â‰¥1% in POMALYST + Low-dose Dex<br> arm, and at least 1% point higher than<br> the High-dose-Dex arm)</span></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule" valign="bottom"><span class="Bold">System Organ Class/Preferred Term</span></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold"><br>POMALYST +<br>Low-dose Dex<br>(N=300)</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">High-dose Dex<br>(N=150)</span></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold"><br>POMALYST +<br>Low-dose Dex<br>(N=300)</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">High-dose Dex<br>(N=150)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Number (%) of patients with at least one adverse reaction</td>
<td class="Botrule Rrule" align="center">297 (99.0)</td>
<td class="Botrule Rrule" align="center">149 (99.3)</td>
<td class="Botrule Rrule" align="center">259 (86.3)</td>
<td class="Botrule Rrule" align="center">127 (84.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Blood and lymphatic system disorders</span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">154 (51.3)</td>
<td class="Botrule Rrule" align="center">31 (20.7)</td>
<td class="Botrule Rrule" align="center">145 (48.3)</td>
<td class="Botrule Rrule" align="center">24 (16.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Botrule Rrule" align="center">89 (29.7) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">44 (29.3) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">66 (22.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">39 (26.0) <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Botrule Rrule" align="center">38 (12.7)</td>
<td class="Botrule Rrule" align="center">8 (5.3)</td>
<td class="Botrule Rrule" align="center">27 (9.0)</td>
<td class="Botrule Rrule" align="center">5 (3.3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">28 (9.3)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
<td class="Botrule Rrule" align="center">28 (9.3)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">General disorders and administration site conditions</span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></td>
<td class="Botrule Rrule" align="center">140 (46.7)</td>
<td class="Botrule Rrule" align="center">64 (42.7)</td>
<td class="Botrule Rrule" align="center">26 (8.7) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">18 (12.0) <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">80 (26.7)</td>
<td class="Botrule Rrule" align="center">35 (23.3)</td>
<td class="Botrule Rrule" align="center">9 (3.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">7 (4.7) <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></td>
<td class="Botrule Rrule" align="center">52 (17.3)</td>
<td class="Botrule Rrule" align="center">17 (11.3)</td>
<td class="Botrule Rrule" align="center">4 (1.3) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">3 (2.0) <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </td>
<td class="Botrule Rrule" align="center">11 (3.7) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">3 (2.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">5 (1.7)</td>
<td class="Botrule Rrule" align="center">1 (0.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">93 (31.0)</td>
<td class="Botrule Rrule" align="center">19 (12.7)</td>
<td class="Botrule Rrule" align="center">9 (3.0)</td>
<td class="Botrule Rrule" align="center">1 (0.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">58 (19.3)</td>
<td class="Botrule Rrule" align="center">20 (13.3)</td>
<td class="Botrule Rrule" align="center">47 (15.7)</td>
<td class="Botrule Rrule" align="center">15 (10.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="40484176" conceptname="Neutropenic sepsis">Neutropenic sepsis</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">3 (1.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">0 (0.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">3 (1.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Rrule" align="center">66 (22.0)</td>
<td class="Botrule Rrule" align="center">28 (18.7)</td>
<td class="Botrule Rrule" align="center">3 (1.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">2 (1.3) <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule Rrule" align="center">65 (21.7)</td>
<td class="Botrule Rrule" align="center">22 (14.7)</td>
<td class="Botrule Rrule" align="center">7 (2.3)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Rrule" align="center">45 (15.0)</td>
<td class="Botrule Rrule" align="center">17 (11.3)</td>
<td class="Botrule Rrule" align="center">3 (1.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">2 (1.3) <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Rrule" align="center">23 (7.7)</td>
<td class="Botrule Rrule" align="center"> 6 (4.0)</td>
<td class="Botrule Rrule" align="center">3 (1.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">59 (19.7)</td>
<td class="Botrule Rrule" align="center">24 (16.0)</td>
<td class="Botrule Rrule" align="center">15 (5.0)</td>
<td class="Botrule Rrule" align="center">6 (4.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone pain</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">54 (18.0)</td>
<td class="Botrule Rrule" align="center">21 (14.0)</td>
<td class="Botrule Rrule" align="center">22 (7.3)</td>
<td class="Botrule Rrule" align="center">7 (4.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></td>
<td class="Botrule Rrule" align="center">46 (15.3)</td>
<td class="Botrule Rrule" align="center">11 (7.3)</td>
<td class="Botrule Rrule" align="center">1 (0.3) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">1 (0.7) <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Botrule Rrule" align="center">26 (8.7)</td>
<td class="Botrule Rrule" align="center">7 (4.7)</td>
<td class="Botrule Rrule" align="center">2 (0.7) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">1 (0.7) <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Botrule Rrule" align="center">20 (6.7) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">9 (6.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">6 (2.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">76 (25.3)</td>
<td class="Botrule Rrule" align="center">25 (16.7)</td>
<td class="Botrule Rrule" align="center">17 (5.7)</td>
<td class="Botrule Rrule" align="center">7 (4.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Botrule Rrule" align="center">60 (20.0)</td>
<td class="Botrule Rrule" align="center">15 (10.0)</td>
<td class="Botrule Rrule" align="center">2 (0.7) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">1 (0.7) <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">Chronic obstructive pulmonary disease</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">5 (1.7) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">0 (0.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">4 (1.3)</td>
<td class="Botrule Rrule" align="center"> 0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span></td>
<td class="Botrule Rrule" align="center">52 (17.3)</td>
<td class="Botrule Rrule" align="center">18 (12.0)</td>
<td class="Botrule Rrule" align="center">5 (1.7) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">2 (1.3) <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center">37 (12.3)</td>
<td class="Botrule Rrule" align="center">14 (9.3)</td>
<td class="Botrule Rrule" align="center">4 (1.3) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">2 (1.3) <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Rrule" align="center">23 (7.7)</td>
<td class="Botrule Rrule" align="center">8 (5.3)</td>
<td class="Botrule Rrule" align="center">1 (0.3) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">0 (0.0) <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Botrule Rrule" align="center">17 (5.7)</td>
<td class="Botrule Rrule" align="center">2 (1.3)</td>
<td class="Botrule Rrule" align="center">2 (0.7) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">0 (0.0) <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">Depressed level of consciousness</span></td>
<td class="Botrule Rrule" align="center">5 (1.7) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">0 (0.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">3 (1.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Metabolism and nutrition disorders</span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Botrule Rrule" align="center">38 (12.7)</td>
<td class="Botrule Rrule" align="center">12 (8.0)</td>
<td class="Botrule Rrule" align="center">3 (1.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">2 (1.3) <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td class="Botrule Rrule" align="center">28 (9.3) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">12 (8.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">12 (4.0)</td>
<td class="Botrule Rrule" align="center">4 (2.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></td>
<td class="Botrule Rrule" align="center">12 (4.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">9 (6.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">5 (1.7)</td>
<td class="Botrule Rrule" align="center">1 (0.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Skin and subcutaneous tissue disorders</span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule Rrule" align="center">23 (7.7)</td>
<td class="Botrule Rrule" align="center">2 (1.3)</td>
<td class="Botrule Rrule" align="center">3 (1.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Botrule Rrule" align="center">22 (7.3)</td>
<td class="Botrule Rrule" align="center">5 (3.3)</td>
<td class="Botrule Rrule" align="center">0 (0.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">0 (0.0) <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></td>
<td class="Botrule Rrule" align="center">15 (5.0)</td>
<td class="Botrule Rrule" align="center">1 (0.7)</td>
<td class="Botrule Rrule" align="center">0 (0.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">0 (0.0) <span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Investigations</span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â Neutrophil count decreased</td>
<td class="Botrule Rrule" align="center">15 (5.0)</td>
<td class="Botrule Rrule" align="center">1 (0.7)</td>
<td class="Botrule Rrule" align="center">14 (4.7)</td>
<td class="Botrule Rrule" align="center">1 (0.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â Platelet count decreased</td>
<td class="Botrule Rrule" align="center">10 (3.3) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">3 (2.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">8 (2.7)</td>
<td class="Botrule Rrule" align="center"> 2 (1.3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â White blood cell count decreased</td>
<td class="Botrule Rrule" align="center">8 (2.7) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">1 (0.7) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">8 (2.7)</td>
<td class="Botrule Rrule" align="center"> 0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> increased</td>
<td class="Botrule Rrule" align="center">7 (2.3) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">2 (1.3) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">5 (1.7)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span> increased</td>
<td class="Botrule Rrule" align="center">4 (1.3) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">2 (1.3) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">3 (1.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â Lymphocyte count decreased</td>
<td class="Botrule Rrule" align="center">3 (1.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">1 (0.7) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">3 (1.0)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Renal and urinary disorders</span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span></td>
<td class="Botrule Rrule" align="center">31 (10.3) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">18 (12.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">19 (6.3)</td>
<td class="Botrule Rrule" align="center">8 (5.3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications</span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="442560" conceptname="Fracture of femur">Femur fracture</span> <span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center">5 (1.7) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">1 (0.7) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">5 (1.7)</td>
<td class="Botrule Rrule" align="center">1 (0.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Reproductive system and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span></span></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">Pelvic pain</span></td>
<td class="Botrule Rrule" align="center">6 (2.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">3 (2.0) <span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center">4 (1.3)</td>
<td class="Botrule Rrule" align="center">0 (0.0)</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Other Adverse Reactions</span><br>Other adverse reactions of POMALYST in patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>, not described above, and considered important:</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Cardiac failure congestive</span><br><span class="Bold">Ear and labyrinth disorders:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>: </span><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span><br><span class="Bold">General disorders and administration site conditions: </span>General physical health deterioration, <span class="product-label-link" type="condition" conceptid="4164649" conceptname="Non-cardiac chest pain">Non-cardiac chest pain</span>, Multi-organ failure<br><span class="Bold">Hepatobiliary disorders:</span> <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>:</span> <span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">Pneumocystis jiroveci pneumonia</span>, <span class="product-label-link" type="condition" conceptid="437222" conceptname="Respiratory syncytial virus infection">Respiratory syncytial virus infection</span>, <span class="product-label-link" type="condition" conceptid="40484176" conceptname="Neutropenic sepsis">Neutropenic sepsis</span>, <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span>, <span class="product-label-link" type="condition" conceptid="436145" conceptname="Pneumonia due to respiratory syncytial virus">Pneumonia respiratory syncytial viral</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">Cellulitis</span>, <span class="product-label-link" type="condition" conceptid="4159744" conceptname="Urosepsis">Urosepsis</span>, <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">Septic shock</span>, <span class="product-label-link" type="condition" conceptid="4307981" conceptname="Clostridium difficile colitis">Clostridium difficile colitis</span>, <span class="product-label-link" type="condition" conceptid="261324" conceptname="Pneumonia due to Streptococcus">Pneumonia streptococcal</span>, <span class="product-label-link" type="condition" conceptid="4133224" conceptname="Lobar pneumonia">Lobar pneumonia</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral infection</span>, <span class="product-label-link" type="condition" conceptid="4028389" conceptname="Infectious disease of lung">Lung infection</span><br><span class="Bold">Investigations:</span> <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Hemoglobin decreased</span><br><span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications: </span><span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Fall</span>, <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">Compression fracture</span>, <span class="product-label-link" type="condition" conceptid="4222001" conceptname="Collapse of vertebra">Spinal compression fracture</span><br><span class="Bold">Metabolism and nutritional disorders:</span> <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="437986" conceptname="Failure to thrive">Failure to thrive</span><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">Depressed level of consciousness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span><br><span class="Bold">Psychiatric disorders: </span>Mental status change<br><span class="Bold">Renal and urinary disorders:</span> <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span><br><span class="Bold">Reproductive system and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">Pelvic pain</span><br><span class="Bold">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial lung disease</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">Respiratory failure</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>: </span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB062"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">The following adverse drug reactions have been identified from the worldwide postmarketing
									experience with POMALYST: <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>), elevated liver enzymes, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> (including fatal cases).
								</p>
<p>Because these reactions are reported voluntarily from a population of uncertain size, it is not
									always possible to reliably estimate their frequency or establish a causal relationship to drug
									exposure.
								</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="SB070"></a><a name="section-7"></a><p></p>
<h1>7		DRUG INTERACTIONS</h1>
<p class="First">Pomalidomide is primarily metabolized by CYP1A2 and CYP3A.  Pomalidomide is also a substrate for P-glycoprotein (P-gp).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="SB071"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Drugs That May Increase Pomalidomide Plasma Concentrations</h2>
<p class="First"><span class="Underline">CYP1A2 inhibitors</span>: Pomalidomide exposure is increased when POMALYST is co-administered with a strong CYP1A2 inhibitor (fluvoxamine) in the presence of a strong CYP3A4/5 and P-gp inhibitor (ketoconazole). Ketoconazole in the absence of a CYP1A2 inhibitor does not increase pomalidomide exposure. Avoid co-administration of strong CYP1A2 inhibitors (e.g. ciprofloxacin and fluvoxamine) [see <span class="Italics">Dosage and Administration (<a href="#SB023">2.3</a>) and Clinical Pharmacology (<a href="#SB123">12.3</a>)</span>]. If it is medically necessary to co-administer strong inhibitors of CYP1A2 in the presence of strong inhibitors of CYP3A4 and P-gp, POMALYST dose should be reduced by 50%.</p>
<p>The effect of a CYP1A2 inhibitor in the absence of a co-administered CYP3A4 and P-gp inhibitor has not been studied. Monitor for toxicities if CYP1A2 inhibitors are to be co-administered in the absence of a co-administered CYP3A4 and P-gp inhibitor, and reduce dose if needed. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB072"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Drugs That May Decrease Pomalidomide Plasma Concentrations</h2>
<p class="First"><span class="Underline">Smoking</span>: Cigarette smoking may reduce pomalidomide exposure due to CYP1A2 induction. Patients should be advised that smoking may reduce the efficacy of pomalidomide.</p>
<p><span class="Underline">CYP1A2 inducers</span>: Co-administration of POMALYST with drugs that are CYP1A2 inducers has not been studied and may reduce pomalidomide exposure.   </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="SB080"></a><a name="section-8"></a><p></p>
<h1>8		USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="SB081"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<p class="First">Pregnancy Category X <span class="Bold">[see </span><span class="Bold Italics"><a href="#e1-b86c-0800200c9a66-jybw">Boxed Warnings</a></span><span class="Bold"> and</span><span class="Bold Italics"> Contraindications (<a href="#SB040">4</a>)</span><span class="Bold">]</span></p>
<p><span class="Italics">Risk Summary</span></p>
<p>POMALYST can cause embryo-fetal harm when administered to a pregnant female and is contraindicated during pregnancy.  POMALYST is a thalidomide analogue.</p>
<p>Thalidomide is a human teratogen, inducing a high frequency of severe and life-threatening <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> such as amelia (absence of limbs), <span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">phocomelia</span> (short limbs), hypoplasticity of the bones, absence of bones, external ear abnormalities (including <span class="product-label-link" type="condition" conceptid="381384" conceptname="Congenital absence of external ear">anotia</span>, micropinna, small or absent external auditory canals), <span class="product-label-link" type="condition" conceptid="374923" conceptname="Bell's palsy">facial palsy</span>, eye abnormalities (<span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmos</span>, <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmos</span>), and congenital heart defects. Alimentary tract, urinary tract, and <span class="product-label-link" type="condition" conceptid="4291794" conceptname="Congenital absence of cervix">genital malformations</span> have also been documented and mortality at or shortly after birth has been reported in about 40% of infants. </p>
<p>Pomalidomide was teratogenic in both rats and rabbits when administered during the period of organogenesis. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.</p>
<p>If pregnancy does occur during treatment, immediately discontinue the drug.  Under these conditions, refer patient to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling.  Report any suspected fetal exposure to POMALYST to the FDA via the MedWatch program at 1-800-FDA-1088 and also to Celgene Corporation at 1-888-423-5436.</p>
<p><span class="Italics">Animal Data</span></p>
<p>Pomalidomide was teratogenic in both rats and rabbits in the embryo-fetal developmental studies when administered during the period of organogenesis.</p>
<p>In rats, pomalidomide was administered orally to pregnant animals at doses of 25 to 1000 mg/kg/day. Malformations or absence of urinary bladder, absence of thyroid gland, and fusion and misalignment of lumbar and thoracic vertebral elements (vertebral, central, and/or neural arches) were observed at all dose levels. There was no maternal toxicity observed in this study.  The lowest dose in rats resulted in an exposure (AUC) approximately 85-fold of the human exposure at the recommended dose of 4 mg/day. Other embryo-fetal toxicities included increased resorptions leading to decreased number of viable fetuses.</p>
<p>In rabbits, pomalidomide was administered orally to pregnant animals at doses of 10 to 250 mg/kg/day. Increased cardiac malformations such as interventricular septal defect were seen at all doses with significant increases at 250 mg/kg/day. Additional malformations observed at 250 mg/kg/day included anomalies in limbs (flexed and/or rotated fore- and/or hindlimbs, unattached or absent digit) and associated skeletal malformations (not ossified metacarpal, misaligned phalanx and metacarpal, absent digit, not ossified phalanx, and short not ossified or bent tibia), moderate dilation of the lateral ventricle in the brain, abnormal placement of the right subclavian artery, absent intermediate lobe in the lungs, low-set kidney, altered liver morphology, incompletely or not ossified pelvis, an increased average for supernumerary thoracic ribs, and a reduced average for ossified tarsals. No maternal toxicity was observed at the low dose (10 mg/kg/day) that resulted in cardiac anomalies in fetuses; this dose resulted in an exposure (AUC) approximately equal to that reported in humans at the recommended dose of 4 mg/day. Additional embryo-fetal toxicity included increased resorption.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="SB083"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">It is not known if pomalidomide is excreted in human milk. Pomalidomide was excreted in the milk of lactating rats. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants from POMALYST, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="SB084"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">Safety and effectiveness of POMALYST in patients below the age of 18 years have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="SB085"></a><a name="section-8.4"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">No dosage adjustment is required for POMALYST based on age.</p>
<p>Of the total number of patients in clinical studies of POMALYST, 44% were aged older than 65 years, while 10% were aged older than 75 years. No overall differences in effectiveness were observed between these patients and younger patients. In these studies, patients older than 65 years were more likely than patients less than or equal to 65 years of age to experience <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB086"></a><a name="section-8.5"></a><p></p>
<h2>8.6	Females of Reproductive Potential and Males</h2>
<p class="First">POMALYST can cause fetal harm when administered during pregnancy [see<span class="Italics"> Use in Specific Populations (<a href="#SB081">8.1</a>)</span>]. Females of reproductive potential must avoid pregnancy while taking POMALYST and for at least 4 weeks after completing therapy. </p>
<p><span class="Underline">Females</span><br>Females of reproductive potential must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously: one highly effective form of contraception â€“ tubal ligation, IUD, hormonal (birth control pills, injections, hormonal patches, vaginal rings, or implants), or partnerâ€™s vasectomy, and 1 additional effective contraceptive method â€“ male latex or synthetic condom, diaphragm, or cervical cap. Contraception must begin 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. Reliable contraception is indicated even where there has been a history of <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>, unless due to hysterectomy. Females of reproductive potential should be referred to a qualified provider of contraceptive methods, if needed.  </p>
<p>Females of reproductive potential must have 2 <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy tests</span> before initiating POMALYST.  The first test should be performed within 10-14 days, and the second test within 24 hours prior to prescribing POMALYST. Once treatment has started and during dose interruptions, pregnancy testing for females of reproductive potential should occur weekly during the first 4 weeks of use, then pregnancy testing should be repeated every 4 weeks in females with regular menstrual cycles. If menstrual cycles are irregular, the pregnancy testing should occur every 2 weeks. Pregnancy testing and counseling should be performed if a patient misses her period or if there is any abnormality in her menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. POMALYST treatment must be discontinued during this evaluation.</p>
<p><span class="Underline">Males</span><br>Pomalidomide is present in the semen of males who take POMALYST. Therefore, males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking POMALYST and for up to 28 days after discontinuing POMALYST, even if they have undergone a successful vasectomy. Male patients taking POMALYST must not donate sperm.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB087"></a><a name="section-8.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Pomalidomide and its metabolites are primarily excreted by the kidneys [see<span class="Italics"> Clinical Pharmacology (<a href="#SB123">12.3</a>)</span>]. The influence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the safety, efficacy, and pharmacokinetics of pomalidomide has not been evaluated.   Patients with serum creatinine greater than 3.0 mg/dL were excluded in clinical studies. Avoid POMALYST in patients with a serum creatinine greater than 3.0 mg/dL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SB088"></a><a name="section-8.7"></a><p></p>
<h2>8.8	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Pomalidomide is metabolized in the liver [see<span class="Italics"> Clinical Pharmacology (<a href="#SB123">12.3</a>)</span>]. The influence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the safety, efficacy, and pharmacokinetics of pomalidomide has not been evaluated. Patients with serum bilirubin greater than 2.0 mg/dL and AST/ALT greater than 3.0 x upper limit normal (ULN) were excluded in clinical studies. Avoid POMALYST in patients with serum bilirubin greater than 2.0 mg/dL and AST/ALT greater than 3.0 x ULN.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="SB100"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE</h1>
<p class="First">No specific information is available on the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with pomalidomide, and it is unknown whether pomalidomide or its metabolites are dialyzable.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="SB110"></a><a name="section-10"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">POMALYST is an immunomodulatory antineoplastic agent. The chemical name is (RS)-4-Amino-2-(2,6-dioxo-piperidin-3-yl)-isoindoline-1,3-dione and it has the following chemical structure:</p>
<p><img alt="Pomalidomide Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66&amp;name=pom-figure-1.jpg"></p>
<p>The empirical formula for pomalidomide is C<span class="Sub">13</span>H<span class="Sub">11</span>N<span class="Sub">3</span>O<span class="Sub">4</span> and the gram molecular weight is 273.24.</p>
<p>Pomalidomide is a yellow solid powder. Â It has limited to low solubility into organic solvents and it has low solubility in all pH solutions (about 0.01 mg/mL). Â Pomalidomide has a chiral carbon atom which exists as a racemic mixture of the R(+) and S(-) enantiomers.</p>
<p>POMALYST is available in 1-mg, 2-mg, 3-mg, and 4-mg capsules for oral administration. Each capsule contains pomalidomide as the active ingredient and the following inactive ingredients: mannitol, pregelatinized starch, and sodium stearyl fumarate. The 1-mg capsule shell contains gelatin, titanium dioxide, FD&amp;C blue 2, yellow iron oxide, white ink, and black ink. The 2-mg capsule shell contains gelatin, titanium dioxide, FD&amp;C blue 2, yellow iron oxide, FD&amp;C red 3, and white ink. The 3-mg capsule shell contains gelatin, titanium dioxide, FD&amp;C blue 2, yellow iron oxide, and white ink. The 4-mg capsule shell contains gelatin, titanium dioxide, FD&amp;C blue 1, FD&amp;C blue 2, and white ink.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="SB120"></a><a name="section-11"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="SB121"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">Pomalidomide, an analogue of thalidomide, is an immunomodulatory agent with antineoplastic activity. In in vitro cellular assays, pomalidomide inhibited proliferation and induced <span class="product-label-link" type="condition" conceptid="4048757" conceptname="Apoptosis">apoptosis</span> of hematopoietic tumor cells. Additionally, pomalidomide inhibited the proliferation of lenalidomide-resistant <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> cell lines and synergized with dexamethasone in both lenalidomide-sensitive and lenalidomide-resistant cell lines to induce tumor cell <span class="product-label-link" type="condition" conceptid="4048757" conceptname="Apoptosis">apoptosis</span>. Pomalidomide enhanced T cell- and natural killer (NK) cell-mediated immunity and inhibited production of pro-inflammatory cytokines (e.g., TNF-Î± and IL-6) by monocytes. Pomalidomide demonstrated anti-angiogenic activity in a mouse tumor model and in the in vitro umbilical cord model.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="AG122"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The QTc prolongation potential of pomalidomide was evaluated in a single center, randomized, double-blind crossover study (N=72) using 4 mg pomalidomide, 20 mg pomalidomide, placebo, and 400 mg moxifloxacin (positive control). No significant QTc prolongation effect of pomalidomide was observed following pomalidomide doses of 4 and 20 mg.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="SB123"></a><a name="section-11.3"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<p class="First"><span class="Underline">Absorption</span><br>Following administration of single oral doses of POMALYST, the maximum plasma concentration (C<span class="Sub">max</span>) for pomalidomide occurs at 2 and 3 hours postdose.  The systemic exposure (AUC) of pomalidomide increases in an approximately dose proportional manner.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> who received POMALYST 4 mg daily alone or in combination with dexamethasone, pomalidomide steady-state drug exposure was characterized by AUC(Î¤) of 400 ngâ€¢h/mL and C<span class="Sub">max</span> of 75 ng/mL. Following multiple doses, pomalidomide has an accumulation ratio of 27% to 31%.</p>
<p><span class="Underline">Distribution</span><br>Pomalidomide has a mean apparent volume of distribution (Vd/F) between 62 and 138 L at steady state. Pomalidomide is distributed in semen of healthy subjects at a concentration of approximately 67% of plasma level at 4 hours postdose (~T<span class="Sub">max</span>) after 4 days of once-daily dosing at 2 mg.  Human plasma protein binding ranges from 12% to 44% and is not concentration dependent. Pomalidomide is a substrate for P-glycoprotein (P-gp).</p>
<p><span class="Underline">Metabolism</span><br>Pomalidomide is primarily metabolized in the liver by CYP1A2 and CYP3A4.  In vitro, CYP1A2 and CYP3A4 were identified as the primary enzymes involved in the CYP-mediated hydroxylation of pomalidomide, with additional minor contributions from CYP2C19 and CYP2D6.</p>
<p><span class="Underline">Elimination</span><br>Pomalidomide is eliminated with a median plasma half-life of approximately 9.5 hours in healthy subjects and approximately 7.5 hours in patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>. Pomalidomide has a mean total body clearance (CL/F) of 7-10 L/h.</p>
<p>Following a single oral administration of [<span class="Sup">14</span>C]-pomalidomide (2 mg) to healthy subjects, approximately 73% and 15% of the radioactive dose was eliminated in urine and feces, respectively, with approximately 2% and 8% of the radiolabeled dose eliminated unchanged as pomalidomide in urine and feces. </p>
<p><span class="Underline">Drug Interactions</span></p>
<p class="Italics">Drugs that Inhibit Pomalidomide Metabolism</p>
<p>CYP1A2 Inhibitors: The effect of CYP1A2 inhibitors, in the absence of a co-administered CYP3A4 and P-gp inhibitor, is unknown.  However, co-administration of fluvoxamine (a strong CYP1A2 inhibitor) in the presence of ketoconazole (a strong CYP3A4 and P-gp inhibitor) to 12 healthy male subjects increased exposure (geometric mean AUC<span class="Sub">INF</span>) to pomalidomide by 146% compared to pomalidomide administered alone [see<span class="Italics"> Dosage and Administration (<a href="#SB022">2.2</a>) and Drug Interactions (<a href="#SB071">7.1</a>)</span>].</p>
<p>Strong CYP3A4 and P-glycoprotein (P-gp) Inhibitors: Co-administration of ketoconazole (a strong CYP3A4 and P-gp inhibitor) in 16 healthy male subjects resulted in an increased exposure (geometric mean AUC<span class="Sub">INF</span>) to pomalidomide of 19% compared to pomalidomide administered alone.</p>
<p class="Italics">Drugs that Induce Pomalidomide Metabolism</p>
<p>Strong CYP1A2 Inducers: Co-administration of POMALYST with drugs that are CYP1A2 inducers has not been studied and may reduce pomalidomide exposure.</p>
<p>Strong CYP3A4 Inducers: Co-administration of carbamazepine to 16 healthy male subjects decreased exposure (geometric mean AUC<span class="Sub">INF</span>) to pomalidomide by 21% compared to pomalidomide administered alone.</p>
<p>Dexamethasone: Co-administration of multiple doses of 4 mg POMALYST with 20 mg to 40 mg dexamethasone (a weak to moderate inducer of CYP3A4) to patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> had no effect on the pharmacokinetics of pomalidomide compared with pomalidomide administered alone.</p>
<p class="Italics">In Vitro Inhibition of Drug Metabolizing Enzymes and Transporters by Pomalidomide</p>
<p>Pomalidomide does not inhibit or induce CYP450 enzymes or transporters in vitro.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="SB130"></a><a name="section-12"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="SB131"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies examining the carcinogenic potential of pomalidomide have not been conducted. One of 12 monkeys dosed with 1 mg/kg of pomalidomide (an exposure approximately 15-fold of the exposure in patients at the recommended dose of 4 mg/day) developed <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">acute myeloid leukemia</span> in a 9-month repeat-dose toxicology study.</p>
<p>Pomalidomide was not mutagenic or clastogenic in a battery of tests, including the bacteria reverse mutation assay (Ames test), the in vitro assay using human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and the micronucleus test in orally treated rats administered doses up to 2000 mg/kg/day.</p>
<p>In a fertility and early embryonic development study in rats, drug-treated males were mated with untreated or treated females. Pomalidomide was administered to males and females at doses of 25 to 1000 mg/kg/day. When treated males were mated with treated females, there was an increase in post-implantation loss and a decrease in mean number of viable embryos at all dose levels. There were no other effects on reproductive functions or the number of pregnancies. The lowest dose tested in animals resulted in an exposure (AUC) approximately 100-fold of the exposure in patients at the recommended dose of 4 mg/day. When treated males in this study were mated with untreated females, all uterine parameters were comparable to the controls.  Based on these results, the observed effects were attributed to the treatment of females.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="SB140"></a><a name="section-13"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SB141"></a><a name="section-13.1"></a><p></p>
<h2>14.1	<span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span></h2>
<p class="First">Trial 1 was a phase 2, multicenter, randomized open-label study in patients with relapsed <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> who were refractory to their last <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">myeloma</span> therapy and had received lenalidomide and bortezomib. Patients were considered relapsed if they had achieved at least stable disease for at least 1 cycle of treatment to at least 1 prior regimen and then developed progressive disease. Patients were considered refractory if they experienced disease progression on or within 60 days of their last therapy. A total of 221 patients were randomized to receive POMALYST alone or POMALYST with Low-dose Dex. In Trial 1, the safety and efficacy of POMALYST 4 mg, once daily for 21 of 28 days, until disease progression, were evaluated alone and in combination with Low-dose Dex (40 mg/day given only on Days 1, 8, 15, and 22 of each 28-day cycle for patients aged 75 years or younger, or 20 mg/day given only on Days 1, 8, 15, and 22 of each 28-day cycle for patients aged greater than 75 years). Patients in the POMALYST alone arm were allowed to add Low-dose Dex upon disease progression.</p>
<p><a href="#table4">Table 4</a> summarizes the baseline patient and disease characteristics in Trial 1. The baseline demographics and disease characteristics were balanced and comparable between the study arms.</p>
<a name="table4"></a><table width="550">
<caption><span>Table 4:	Baseline Demographic and Disease-Related Characteristics â€“ Trial 1</span></caption>
<tfoot><tr class="First Last"><td colspan="3">Data cutoff: 01 April 2011</td></tr></tfoot>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Lrule Rrule">Â Â </td>
<td class="Botrule Rrule" align="center"><span class="Bold">Â Â <br>POMALYST<br>Â Â (n=108)</span></td>
<td class="Botrule Rrule" align="center"><span class="Bold">Â Â POMALYST <br>+ Low-dose<br> Dex<br>Â Â (n=113)</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><span class="Bold">Â Â Patient Characteristics</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Â Â Median age, years (range)</td>
<td class="Botrule Rrule" align="center">Â Â 61 (37-88)</td>
<td class="Botrule Rrule" align="center">Â Â 64 (34-88)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Age distribution, n (%)<br>Â Â Â Â  &lt;65 years<br>Â Â Â Â  â‰¥65 years</td>
<td class="Botrule Rrule" align="center">Â <br>Â Â 65 (60.2)<br>Â Â 43 (39.8)</td>
<td class="Botrule Rrule" align="center">Â <br>Â Â 60 (53.1)<br>Â Â 53 (46.9)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Sex, n (%)<br>Â Â Â Â Male<br>Â Â Â Â Female</td>
<td class="Botrule Rrule" align="center">
<br>Â Â 57 (52.8)<br>Â Â 51 (47.2)</td>
<td class="Botrule Rrule" align="center">
<br>Â Â 62 (54.9)<br>Â Â 51 (45.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Race/ethnicity, n (%)<br>Â Â Â Â White<br>Â Â Â Â Black or African American<br>Â Â Â Â All other race</td>
<td class="Botrule Rrule" align="center">Â <br>Â Â 86 (79.6)<br>Â Â 16 (14.8)<br>Â Â 6 (5.6)</td>
<td class="Botrule Rrule" align="center">Â <br>Â Â 92 (81.4)<br>Â Â 17 (15)<br>Â Â 4 (3.6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â ECOG Performance, n (%)<br>Â Â Status 0-1</td>
<td class="Botrule Rrule" align="center">Â <br>Â Â 95 (87.9)</td>
<td class="Botrule Rrule" align="center">Â <br>Â Â 100 (88.5)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><span class="Bold">Â Â Disease Characteristics</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Number of prior therapies<br>Â Â Â Â Median, (min, max)</td>
<td class="Botrule Rrule" align="center">Â <br>Â Â 5 (2, 12)</td>
<td class="Botrule Rrule" align="center">Â <br>Â Â 5 (2, 13)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Prior transplant, n (%)</td>
<td class="Botrule Rrule" align="center">Â Â 82 (75.9)</td>
<td class="Botrule Rrule" align="center">Â Â 84 (74.3)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule">Â Â Refractory to bortezomib <br>Â Â and lenalidomide, n (%)</td>
<td class="Botrule Rrule" align="center">Â Â 64 (59.3)</td>
<td class="Botrule Rrule" align="center">Â Â 69 (61.1)</td>
</tr>
</tbody>
</table>
<p><a href="#table5">Table 5</a> summarizes the analysis results of overall response rate (ORR) and duration of response (DOR), based on assessments by the Independent Review Adjudication Committee for the treatment arms in Trial 1. ORR did not differ based on type of prior antimyeloma therapy.</p>
<a name="table5"></a><table width="550">
<caption><span>Table 5:	Trial 1 Results</span></caption>
<tfoot><tr class="First Last"><td colspan="3">
<span class="Sup">a</span> Results are prior to the addition of dexamethasone.
												<br><span class="Sup">b</span> ORR = PR + CR per EBMT criteria.
												<br>CI, confidence interval; NE, not established (the median has not yet been reached).<br>Data cutoff: 01 April 2011</td></tr></tfoot>
<tbody class="Headless">
<tr class="First" valign="top">
<td class="Botrule Lrule Rrule">Â Â </td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">Â Â POMALYST <span class="Sup">a</span><br>Â Â (n=108)</span></td>
<td class="Botrule Rrule" align="center"><span class="Bold">Â Â POMALYST + <br>Â Â Low-dose Dex<br>Â Â (n=113)</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><span class="Bold">Â Â Response</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Overall Response Rate <br>Â Â (ORR),<span class="Sup">b</span>  n (%)</td>
<td class="Botrule Rrule" align="center">Â Â 8 (7.4)</td>
<td class="Botrule Rrule" align="center">Â Â 33 (29.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â 95% CI for ORR (%)</td>
<td class="Botrule Rrule" align="center">Â Â (3.3, 14.1)</td>
<td class="Botrule Rrule" align="center">Â Â (21.0, 38.5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Complete Response (CR), n (%)</td>
<td class="Botrule Rrule" align="center">Â Â 0 (0.0)</td>
<td class="Botrule Rrule" align="center">Â Â 1 (0.9)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Â Â Partial Response (PR), n (%)</td>
<td class="Botrule Rrule" align="center">Â Â 8 (7.4)</td>
<td class="Botrule Rrule" align="center">Â Â 32 (28.3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Â Â Duration of Response (DOR)</span></td>
<td class="Botrule Rrule" valign="bottom">Â Â </td>
<td class="Botrule Rrule" valign="bottom">Â Â </td>
</tr>
<tr valign="middle">
<td class="Botrule Lrule Rrule">Â Â Median, months</td>
<td class="Botrule Rrule" align="center">Â Â NE</td>
<td class="Botrule Rrule" align="center">Â Â 7.4</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule">Â Â 95% CI for DOR (months)</td>
<td class="Botrule Rrule" align="center">Â Â NE</td>
<td class="Botrule Rrule" align="center">Â Â (5.1, 9.2)</td>
</tr>
</tbody>
</table>
<p>Trial 2 was a Phase 3 multi-center, randomized, open-label study, where POMALYST + Low-dose Dex therapy was compared to High-dose Dex in adult patients with relapsed and refractory <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>, who had received at least two prior treatment regimens, including lenalidomide and bortezomib, and demonstrated disease progression on or within 60 days of the last therapy. Patients with creatinine clearance â‰¥ 45mL/min qualified for the trial. A total of 455 patients were enrolled in the trial: 302 in the POMALYST + Low-dose Dex arm and 153 in the High-dose Dex arm. Patients in the POMALYST + Low-dose Dex arm were administered 4 mg POMALYST orally on Days 1 to 21 of each 28-day cycle. Dexamethasone (40 mg) was administered once per day on Days 1, 8, 15 and 22 of a 28-day cycle. Patients &gt; 75 years of age started treatment with 20 mg dexamethasone using the same schedule. For the High-dose Dex arm, dexamethasone (40 mg) was administered once per day on Days 1 through 4, 9 through 12, and 17 through 20 of a 28-day cycle. Patients &gt; 75 years of age started treatment with 20 mg dexamethasone using the same schedule. Treatment continued until patients had disease progression. </p>
<p>Baseline patient and disease characteristics were balanced and comparable between the study arms, as summarized in <a href="#table6">Table 6</a>. Overall, 94% of patients had disease refractory to lenalidomide, 79% had disease refractory to bortezomib and 74% had disease refractory to both lenalidomide and bortezomib.</p>
<a name="table6"></a><table width="500">
<caption><span>Table 6: Baseline Demographic and Disease-Related Characteristics â€“ Trial 2</span></caption>
<col width="40%">
<col width="20%">
<col width="40%">
<tfoot><tr class="First Last"><td colspan="3">Data cutoff: 01March 2013</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center">Â </td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">POMALYST +
												Low-dose Dex<br>
												(N=302)</span></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">High-dose Dex <br> Â <br> 
												(N=153)</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><span class="Bold">Patient Characteristics</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Median Age, years (range)</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">64 (35, 84)</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">65 (35, 87)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Age Distribution n (%)<br>&lt; 65 years
												<br>â‰¥ 65 years
											</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <br>158 (52)
												<br>144 (48)
											</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <br>74 (48)
												<br>79 (52)
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Sex n (%)<br>
												Male<br>
												Female
											</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <br>181 (60)<br>
												121 (40)
											</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <br>87 (57)<br>
												66 (43)
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Race/Ethnicity n (%)
												<br>White
												<br>Black or African American
												<br>Asian
												<br>Other Race
												<br>Not Collected
											</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <br>244 (81)
												<br>4 (1)
												<br>4 (1)
												<br>2 (1)
												<br>48 (16)
											</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <br>113 (74)
												<br>3 (2)
												<br>0 (0)
												<br>2 (1)
												<br>35 (23)
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">ECOG Performance n (%)
												<br>Status 0
												<br>Status 1
												<br>Status 2
												<br>Status 3
												<br>Missing
											</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <br>110 (36)
												<br>138 (46)
												<br>52 (17)
												<br>0 (0)
												<br>2 (1)
											</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <br>36 (24)
												<br>86 (56)
												<br>25 (16)
												<br>3 (2)
												<br>3 (2)
											</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><span class="Bold">Disease Characteristics</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Number of Prior Therapies<br>Median, (Min, Max)</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <br>5 (2, 14)</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">Â <br>5 (2, 17)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Prior stem cell transplant n (%)</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">214 (71)</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">105 (69)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">Refractory to bortezomib and lenalidomide n (%)</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">225 (75)</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">113 (74)</td>
</tr>
</tbody>
</table>
<p><a href="#table7">Table 7</a> summarizes the progression free survival (PFS) and overall response rate (ORR) based on the assessment by the Independent Review Adjudication Committee (IRAC) review at the final PFS analysis and overall survival (OS) at the OS analysis. PFS was significantly longer with POMALYST + Low-dose Dex than High-dose Dex:  HR 0.45 (95% CI: 0.35-0.59 p &lt; 0.001).  OS was also significantly longer with POMALYST + Low-dose Dex than High-dose Dex:  HR 0.70 (95% CI: 0.54-0.92 p = 0.009).The Kaplan-Meier curves for PFS and OS for the ITT population are provided in <a href="#figure1">Figures 1</a> and <a href="#figure2">2</a>, respectively.</p>
<a name="table7"></a><table width="600">
<caption><span>Table 7:	Trial 2 Results</span></caption>
<col width="50%">
<col width="25%">
<col width="25%">
<tfoot><tr class="First Last"><td colspan="3">Note: CI=Confidence interval; HD-Dex=High dose dexamethasone; IRAC=Independent Review Adjudication Committee; LD-Dex=Low dose dexamethasone.<br><span class="Sup">a</span> The median is based on Kaplan-Meier estimate.<br><span class="Sup">b</span> Based on Cox proportional hazards model comparing the hazard functions associated with treatment groups, stratified by age (â‰¤75 vs &gt;75), diseases population (refractory to both Lenalidomide and Bortezomib vs not refractory to both drugs), and prior number of antimyeloma therapy (=2 vs &gt;2), stratification factors for the trial.<br><span class="Sup">c</span> The p-value is based on a stratified log-rank test with the same stratification factors as the above Cox model.<br><span class="Sup">d</span> 53% of patients in the High-dose Dex arm subsequently received POMALYST.  <br><span class="Sup">e</span> Based on Cox proportional hazards model (unstratified) comparing the hazard functions associated with treatment groups. <br><span class="Sup">f</span> The p-value is based on an unstratified log-rank test.<br><span class="Sup">g</span>Alpha control for PFS and OS. <br>
												Data cutoff: 07 Sep 2012 for PFS<br>
												Data cutoff: 01 Mar 2013 for OS and ORR
											</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center">Â </td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">POMALYST +
												Low-dose Dex<br>
												(N=302)</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">High-dose Dex <br> Â <br>
												(N=153)</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><span class="Bold">Progression Free Survival Time </span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Number (%) of events</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">164 (54.3)</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">103 (67.3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Median<span class="Sup">a</span> (2-sided 95% CI) <span class="Bold">(months)</span>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">3.6 [3.0, 4.6]</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">1.8 [1.6, 2.1]</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Hazard Ratio (Pom+LD-Dex:HD-Dex) 2-Sided 95% CI<span class="Sup">b</span>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">0.45 [0.35, 0.59]</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Log-Rank Test 2-sided P-Value<span class="Sup">c</span>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top">&lt;0.001</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><span class="Bold">Overall Survival Time<span class="Sup">d</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Number (%) of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">147 (48.7)</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">86 (56.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Median<span class="Sup">a</span> (2-sided 95% CI) <span class="Bold">(months)</span>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">12.4 [10.4, 15.3]</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">8.0[6.9, 9.0]</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">Hazard Ratio (Pom+LD-Dex:HD-Dex) 2-Sided 95% CI<span class="Sup">e</span>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">0.70 [0.54, 0.92]</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Log-Rank Test 2-sided P-Value <span class="Sup">f, g</span>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top">0.009</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Overall Response Rate, n (%)</span></td>
<td class="Botrule Lrule Rrule" align="center">71 (23.5)</td>
<td class="Botrule Lrule Rrule" align="center">6 (3.9)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â Â Complete Response</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">1 (0.3)</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">Â Â Very Good Partial Response</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">8 (2.6)</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">1 (0.7)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">Â Â Partial Response</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">62 (20.5)</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">5 (3.3)</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 1: Progression Free Survival Based on IRAC Review of Response by IMWG Criteria (Stratified Log Rank Test) (ITT Population)</span></p>
<p><a name="figure1"></a><img alt="Progression Free Survival Based on IRAC Review of Response by IMWG Criteria " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66&amp;name=pom-figure-10.jpg"></p>
<p>Data cut-off: 07 Sep 2012</p>
<p><span class="Bold"> Figure 2: Kaplan-Meier Curve of Overall Survival (ITT Population)</span></p>
<p><a name="figure2"></a><img alt="Kaplan-Meier Curve of Overall Survival" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66&amp;name=pom-figure-11.jpg"></p>
<p>Data cutoff: 01 Mar 2013</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="SB150"></a><a name="section-14"></a><p></p>
<h1>15	REFERENCES</h1>
<p class="First">1.Â Â Â Â Â Â Â OSHA Hazardous Drugs. <span class="Italics">OSHA</span>.  [Accessed on 29 January 2013, from http://www.osha.gov/SLTC/hazardousdrugs/index.html]</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="SB160"></a><a name="section-15"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="SB161"></a><a name="section-15.1"></a><p></p>
<h2>16.1	How Supplied</h2>
<p class="First">Dark blue opaque cap and yellow opaque body, imprinted â€œPOMLâ€? on the cap in white ink and â€œ1 mgâ€? on the body in black ink
									<br>Â Â Â Â 1 mg bottles of 21Â Â Â Â Â Â Â Â (NDC 59572-501-21)
									<br>Â Â Â Â 1 mg bottles of 100Â Â Â Â Â Â (NDC 59572-501-00)
								</p>
<p>Dark blue opaque cap and orange opaque body, imprinted â€œPOMLâ€? on the cap and â€œ2 mgâ€? on the body in white ink
									<br>Â Â Â Â 2 mg bottles of 21Â Â Â Â Â Â Â Â (NDC 59572-502-21)
									<br>Â Â Â Â 2 mg bottles of 100Â Â Â Â Â Â (NDC 59572-502-00)
								</p>
<p>Dark blue opaque cap and green opaque body, imprinted â€œPOMLâ€? on the cap and â€œ3 mgâ€? on the body in white ink
									<br>Â Â Â Â 3 mg bottles of 21Â Â Â Â Â Â Â Â (NDC 59572-503-21)
									<br>Â Â Â Â 3 mg bottles of 100Â Â Â Â Â Â (NDC 59572-503-00)
								</p>
<p>Dark blue opaque cap and blue opaque body, imprinted â€œPOMLâ€? on the cap and â€œ4 mgâ€? on the body in white ink
									<br>Â Â Â Â 4 mg bottles of 21Â Â Â Â Â Â Â  (NDC 59572-504-21)
									<br>Â Â Â Â 4 mg bottles of 100Â Â Â Â Â Â (NDC 59572-504-00)
								</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="SB162"></a><a name="section-15.2"></a><p></p>
<h2>16.2	Storage</h2>
<p class="First">Store at 20Â°C-25Â°C (68Â°F-77Â°F); excursions permitted to 15Â°C-30Â°C (59Â°F-86Â°F).  [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="SB163"></a><a name="section-15.3"></a><p></p>
<h2>16.3	Handling and Disposal</h2>
<p class="First">Care should be exercised in handling of POMALYST. POMALYST capsules should not be opened or crushed. If powder from POMALYST contacts the skin, wash the skin immediately and thoroughly with soap and water. If POMALYST contacts the mucous membranes, flush thoroughly with water.</p>
<p>Follow procedures for proper handling and disposal of anticancer drugs.<span class="Sup">1</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="SB170"></a><a name="section-16"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved Patient Labeling (<span class="Italics"><a href="#SB180">Medication Guide</a></span>)</p>
<p><span class="Underline">Embryo-Fetal Toxicity</span><br>Advise patients that POMALYST is contraindicated in pregnancy [see<span class="Italics"> Contraindications (<a href="#SB040">4</a>)</span>]. POMALYST is a thalidomide analogue and may cause serious <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to a developing baby [see<span class="Italics"> Warnings and Precautions (<a href="#SB051">5.1</a>)</span> and <span class="Italics">Use in Specific Populations (<a href="#SB081">8.1</a>)</span>].<br>Â Â </p>
<ul>
<li>Advise females of reproductive potential that they must avoid pregnancy while taking POMALYST and for at least 4 weeks after completing therapy. </li>
<li>Initiate POMALYST treatment in females of reproductive potential only following a <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span>.  </li>
<li>Advise females of reproductive potential of the importance of monthly pregnancy tests and the need to use 2 different forms of contraception, including at least 1 highly effective form, simultaneously during POMALYST therapy, during therapy interruption, and for 4 weeks after she has completely finished taking POMALYST. Highly effective forms of contraception other than tubal ligation include IUD and hormonal (birth control pills, injections, patch, or implants) and a partnerâ€™s vasectomy. Additional effective contraceptive methods include latex or synthetic condom, diaphragm, and cervical cap.</li>
<li>Instruct patient to immediately stop taking POMALYST and contact her doctor if she becomes pregnant while taking this drug, if she misses her menstrual period or experiences unusual menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, if she stops taking birth control, or if she thinks FOR ANY REASON that she may be pregnant.</li>
<li>Advise patient that if her doctor is not available, she can call 1-888-668-2528 for information on emergency contraception [see<span class="Italics"> Warnings and Precautions (<a href="#SB051">5.1</a>)</span> and <span class="Italics">Use in Specific Populations (<a href="#SB086">8.6</a>)</span>].Â Â </li>
<li>Advise males to always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking POMALYST and for up to 28 days after discontinuing POMALYST, even if they have undergone a successful vasectomy.</li>
<li>Advise male patients taking POMALYST that they must not donate sperm [see<span class="Italics"> Warnings and Precautions (<a href="#SB051">5.1</a>) </span>and <span class="Italics">Use in Specific Populations (<a href="#SB086">8.6</a>)</span>].Â Â </li>
<li>All patients must be instructed to not donate blood while taking POMALYST and for 1 month following discontinuation of POMALYST [see<span class="Italics"> Warnings and Precautions (<a href="#SB051">5.1</a>)</span> and <span class="Italics">Use in Specific Populations (<a href="#SB086">8.6</a>)</span>].</li>
</ul>
<p><span class="Underline">POMALYST REMS Program</span><br>Because of the risk of embryo-fetal toxicity, POMALYST is only available through a restricted program called <span class="Underline">POMALYST REMS</span> [see<span class="Italics">  Warnings and Precautions (<a href="#SB052">5.2</a>)</span>].Â Â </p>
<ul>
<li>Patients must sign a Patient-Physician Agreement Form and comply with the requirements to receive POMALYST. In particular, females of reproductive potential must comply with the pregnancy testing, contraception requirements and participate in monthly telephone surveys. Males must comply with the contraception requirements [see<span class="Italics"> Use in Specific Populations (<a href="#SB086">8.6</a>)</span>].Â Â </li>
<li>POMALYST is available only from pharmacies that are certified in POMALYST REMS. Provide patients with the telephone number and Web site for information on how to obtain the product.</li>
</ul>
<p><span class="Underline">Venous and Arterial <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span></span><br>Inform patients of the risk of developing DVT, PE, MI, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and to report immediately any signs and symptoms suggestive of these events for evaluation [see <span class="Italics"><a href="#e1-b86c-0800200c9a66-jybw">Boxed Warnings</a> and Warnings and Precautions (<a href="#SB053">5.3</a>)</span>].</p>
<p><span class="Underline">Hematologic Toxicities</span><br>Inform patients on the risks of developing <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and the need to report signs and symptoms associated with these events to their healthcare provider for further evaluation [see <span class="Italics">Warnings and Precautions (<a href="#SB054">5.4</a>)</span>].</p>
<p><span class="Underline">Hepatotoxicity</span><br>Inform patients on the risks of developing hepatotoxicity, including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, and to report signs and symptoms associated with these events to their healthcare provider for evaluation [see <span class="Italics">Warnings and Precautions (<a href="#SB055">5.5</a>)</span>].</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span><br>Inform patients of the risk for <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> and to report any signs and symptoms associated with these events to their healthcare provider for evaluation [<span class="Italics">see Warnings and Precautions (<a href="#SB056">5.6</a>)</span>].</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional State</span></span><br>Inform patients of the potential risk of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span> with the drug, to avoid situations where <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span> may be a problem, and not to take other medications that may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span> without adequate medical advice [see <span class="Italics">Warnings and Precautions (<a href="#SB057">5.7</a>)</span>].</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></span><br>Inform patients of the risk of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> and to report the signs and symptoms associated with these events to their healthcare provider for further evaluation [see <span class="Italics">Warnings and Precautions (<a href="#SB058">5.8</a>)</span>].</p>
<p><span class="Underline">Second Primary Malignancies</span><br>Inform the patient that the potential risk of developing acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> during treatment with POMALYST is unknown [see <span class="Italics">Warnings and Precautions (<a href="#SB059">5.9</a>)</span>].</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span></span><br>Inform patients of the potential risk of <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span> and to report any signs and symptoms associated with this event to their healthcare provider for evaluation [see <span class="Italics">Warnings and Precautions (<a href="#AG510">5.10</a>)</span>].</p>
<p><span class="Underline">Dosing Instructions</span><br>Inform patients on how to take POMALYST [see<span class="Italics"> Dosage and Administration (<a href="#SB021">2.1</a>)</span>]</p>
<ul>
<li>POMALYST should be taken once daily at about the same time each day.</li>
<li>POMALYST should be taken without food (at least 2 hours before or 2 hours after a meal).</li>
<li>The capsules should not be opened, broken, or chewed.  POMALYST should be swallowed whole with water.</li>
<li>Instruct patients that if they miss a dose of POMALYST, they may still take it up to 12 hours after the time they would normally take it. If more than 12 hours have elapsed, they should be instructed to skip the dose for that day. The next day, they should take POMALYST at the usual time. Warn patients not to take 2 doses to make up for the one that they missed.</li>
</ul>
<p><span class="Underline">Other Information</span><br>Advise patients who smoke to stop because smoking may reduce the efficacy of pomalidomide [see<span class="Italics"> Drug Interactions (<a href="#SB072">7.2</a>)</span>].</p>
<table class="Noautorules"><tbody class="Headless">
<tr valign="top">
<td align="left">Manufactured for:Â Â </td>
<td align="left">Celgene Corporation</td>
</tr>
<tr valign="top">
<td align="left"></td>
<td align="left">Summit, NJ 07901</td>
</tr>
</tbody></table>
<p>POMALYST<span class="Sup">Â®</span>, REVLIMID<span class="Sup">Â®</span>, THALOMID<span class="Sup">Â®</span>, and POMALYST REMS<span class="Sup">Â®</span> are registered trademarks of Celgene Corporation.<br>
							Pat. http://www.celgene.com/therapies<br>
							Â© 2005-2015 Celgene CorporationÂ Â Â All rights reserved.<br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â POMPI.004/MG.004   04/2015</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="SB180"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE<br>POMALYST<span class="Sup">Â®</span> (POM-uh-list)<br>(pomalidomide)<br>capsules<br><br></span></p>
<p><a name="MostImportant"></a><span class="Bold">What is the most important information I should know about POMALYST?</span><br><br></p>
<ul>
<li>Before you begin taking POMALYST, you must read and agree to all of the instructions in the POMALYST REMS<span class="Sup">Â®</span> program.<br><br>
</li>
<li>POMALYST may cause serious side effects including:
								<br><br><span class="Bold">Possible <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> (deformed babies) or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of an unborn baby.</span> Females who are pregnant or who plan to become pregnant must not take POMALYST.
								<br><br><span class="Bold">POMALYST is similar to the medicine thalidomide (THALOMID).</span> We know thalidomide can cause severe life-threatening <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. POMALYST has not been tested in pregnant women. POMALYST has harmed unborn animals in animal testing.
								<br><br><span class="Bold">Females must not get pregnant:</span><ul>
<li>For at least 4 weeks before starting POMALYST</li>
<li>While taking POMALYST</li>
<li>During any breaks (interruptions) in your treatment with POMALYST</li>
<li>For at least 4 weeks after stopping POMALYST</li>
</ul>
<br><span class="Bold">If you become pregnant while taking POMALYST, stop taking it right away and call your healthcare provider. </span>If your healthcare provider is not available, you can call 1-888-668-2528 for medical information. Healthcare providers and patients should report all cases of pregnancy to:
								<ul>
<li>FDA MedWatch at 1-800-FDA-1088, and</li>
<li>Celgene Corporation at 1-888-423-5436</li>
</ul>
<br><span class="Bold">POMALYST can pass into human semen:</span><ul>
<li>Males, including those who have had a vasectomy, must use a latex or synthetic condom during any sexual contact with a pregnant female or a female that can become pregnant while taking POMALYST, during any breaks (interruptions) in your treatment with POMALYST, and for 4 weeks after stopping POMALYST<br><br>
</li>
<li>Do not have unprotected sexual contact with a female who is or could become pregnant. Tell your healthcare provider if you do have unprotected sexual contact with a female who is or could become pregnant<br><br>
</li>
<li>Do not donate sperm while taking POMALYST, during any breaks (interruptions) in your treatment, and for 4 weeks after stopping POMALYST. If a female becomes pregnant with your sperm, the baby may be exposed to POMALYST and may be born with <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span></li>
</ul>
</li>
</ul>
<p><span class="Bold">Â Â Â Â Â Â Men, if your female partner becomes pregnant, you should call your healthcare provider right away.<br><br></span></p>
<ul class="Disc">
<li>
<span class="Bold">Blood clots in your arteries, veins, and lungs, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> can happen if you take POMALYST.</span> Most people who take POMALYST will also take a blood thinner medicine to help prevent blood clots.
									<p class="First">Before taking POMALYST, tell your healthcare provider:</p>
<ul class="Circle">
<li>If you have had a blood clot in the past</li>
<li>If you have high blood pressure, smoke, or if you have been told you have a high level of fat in your blood (<span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>)</li>
<li>About all the medicines you take.  Certain other medicines can also increase your risk for blood clots</li>
</ul>
<p>Call your healthcare provider or get medical help right away if you get any of the following during treatment with POMALYST:</p>
</li>
<li>
<span class="Bold">Signs or symptoms of a blood clot in the lung, arm, or leg may include</span>: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, or arm or leg <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></li>
<li>
<span class="Bold">Signs or symptoms of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> may include</span>: <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> that may spread to the arms, neck, jaw, back, or stomach area (abdomen), feeling <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweaty</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, feeling sick or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>
<span class="Bold">Signs or symptoms of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> may include</span>: sudden <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, especially on one side of the body, severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or problems with vision, speech, or balance</li>
</ul>
<p><span class="Bold">What is POMALYST?</span></p>
<p>POMALYST is a prescription medicine, taken along with the medicine dexamethasone, used to treat people with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> who:</p>
<ul>
<li>Have received at least 2 prior medicines to treat <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>, including a type of medicine known as a proteasome inhibitor and lenalidomide, <span class="Bold">and</span>
</li>
<li>Their disease has become worse during treatment or within 60 days of finishing the last treatment</li>
</ul>
<p>It is not known if POMALYST is safe and effective in people under 18 years of age.<br><br></p>
<p><a name="ShouldNotTake"></a><span class="Bold">Who should not take POMALYST?</span></p>
<p>Do not take POMALYST if you are pregnant, plan to become pregnant, or become pregnant during treatment with POMALYST. <span class="Bold">See â€œ<a href="#MostImportant">What is the most important information I should know about POMALYST?</a>â€?</span></p>
<p><span class="Bold">What should I tell my healthcare provider before taking POMALYST?</span></p>
<p>Before you take POMALYST, tell your healthcare provider if you:</p>
<ul>
<li>Smoke cigarettes</li>
<li>Have any other medical conditions</li>
<li>Are breastfeeding. POMALYST must not be used by women who are breastfeeding. It is not known if POMALYST passes into your breast milk and can harm your baby<br><br>
</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, </span>including prescription and over-the-counter medicines, vitamins, and herbal supplements. POMALYST and other medicines may affect each other, causing serious side effects. Talk with your healthcare provider before taking any new medicines.</p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist.<br><br></p>
<p><span class="Bold">How should I take POMALYST?</span></p>
<p>Take POMALYST exactly as prescribed and follow all the instructions of the POMALYST REMS program.</p>
<p>Before prescribing POMALYST, your healthcare provider will:</p>
<ul class="Circle">
<li>Explain the POMALYST REMS program to you</li>
<li>Have you sign the Patient-Physician Agreement Form</li>
</ul>
<ul>
<li>Swallow POMALYST capsules whole with water 1 time a day. <span class="Bold">Do not break, chew, or open your capsules</span><br>
</li>
<li>Take POMALYST at about the same time each day<br>
</li>
<li>
<span class="Bold">POMALYST should be taken without food</span>, at least 2 hours before or 2 hours after a meal<br>
</li>
<li>Do not open the POMALYST capsules or handle them any more than needed. If you touch a broken POMALYST capsule or the medicine in the capsule, wash the area of your body right away with soap and water<br>
</li>
<li>If you miss a dose of POMALYST and it has been less than 12 hours since your regular time, take it as soon as you remember. If it has been more than 12 hours, just skip your missed dose. Do <span class="Bold">not</span> take 2 doses at the same time<br>
</li>
<li>If you take too much POMALYST, call your healthcare provider right away</li>
</ul>
<p><span class="Bold">Females who can become pregnant:</span><br></p>
<ul>
<li>Will have pregnancy tests weekly for 4 weeks, then every 4 weeks if your menstrual cycle is regular, or every 2 weeks if your menstrual cycle is irregular. 
								<br>If you miss your period or have unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, you will need to have a pregnancy test and receive counseling
							</li>
<li>Must agree to use 2 different forms of effective birth control at the same time, for at least 4 weeks before, while taking, during any breaks (interruptions) in your treatment, and for at least 4 weeks after stopping POMALYST</li>
</ul>
<p><span class="Bold">Males who take POMALYST, </span>even those who have had a vasectomy, must agree to use a latex or synthetic condom during sexual contact with a pregnant female or a female who can become pregnant.</p>
<p><a name="AvoidWhileTaking"></a><span class="Bold">What should I avoid while taking POMALYST?</span><br></p>
<ul>
<li>See â€œ<a href="#MostImportant">What is the most important information I should know about POMALYST?</a>â€?</li>
<li>
<span class="Bold">Females: Do not get pregnant and do not breastfeed while taking POMALYST
								<br>Males: Do not donate sperm</span><br>
</li>
<li>
<span class="Bold">Do not share POMALYST with other people. </span>It may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and other serious problems<br>
</li>
<li>
<span class="Bold">Do not donate blood </span> while you take POMALYST, during any breaks (interruptions) in your treatment, and for 4 weeks after stopping POMALYST. If someone who is pregnant gets your donated blood, her baby may be exposed to POMALYST and may be born with <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span><br>
</li>
<li>You should not smoke cigarettes while taking POMALYST. Smoking cigarettes during treatment with POMALYST may affect how well POMALYST works</li>
<li>POMALYST can cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>. Avoid taking other medicines that may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> during treatment with POMALYST. Avoid situations that require you to be alert until you know how POMALYST affects you</li>
</ul>
<p><span class="Bold">What are the possible side effects of POMALYST?<br>POMALYST may cause serious side effects, including:</span><br></p>
<ul>
<li>See â€œ<a href="#MostImportant">What is the most important information I should know about POMALYST?</a>â€?<br>
</li>
<li>
<span class="Bold">Low white blood cells (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>), low platelets (<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>), and low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>). POMALYST may cause low white blood cells, low platelets, and low red blood cells. </span>You may need a blood transfusion or certain medicines if your blood counts drop too low. Your blood counts should be checked weekly for the first 8 weeks of treatment and monthly thereafter<br>
</li>
<li>
<span class="Bold">Severe liver problems, including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> Tell your healthcare provider right away if you develop any of the following symptoms of liver problems:
							<ul>
<li>Yellowing of your skin or the white part of your eyes (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</li>
<li>Dark or brown (tea-colored) urine</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> on the upper right side of your stomach area (abdomen)</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> more easily than normal</li>
<li>Feeling very tired</li>
</ul>
<p class="First">Your healthcare provider should do blood tests to check your liver function during your treatment with POMALYST.</p>
</li>
<li>
<span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> and severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.</span> Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> and severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> can happen with <span class="Bold">POMALYST</span>.  Call your healthcare provider if you have any symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> including: <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your lips, mouth, tongue, or throat; or if you develop trouble breathing; or if you develop a <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> during treatment with <span class="Bold">POMALYST</span>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">Nerve damage</span></span>. Stop taking POMALYST and call your healthcare provider if you develop symptoms of <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> including: <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> in your hands, legs, or feet</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span> (TLS). </span>TLS is caused by the fast breakdown of cancer cells. TLS can cause <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> and the need for dialysis treatment, abnormal heart rhythm, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, and sometimes <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Your healthcare provider may do blood tests to check you for TLS</li>
</ul>
<p>Your healthcare provider may tell you to stop taking POMALYST if you develop certain serious side effects during treatment.</p>
<p>The most common side effects of POMALYST include:<br><br></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
</ul>
<p>These are not all the possible side effects of POMALYST. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.<br></p>
<p><span class="Bold">How should I store POMALYST?</span></p>
<ul>
<li>Store POMALYST at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C)</li>
<li>Return any unused POMALYST to Celgene or your healthcare provider<br>
</li>
</ul>
<p><span class="Bold">Keep POMALYST and all medicines out of the reach of children.</span><br><br></p>
<p><span class="Bold">General information about the safe and effective use of POMALYST</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. <span class="Bold">Do not</span> take POMALYST for conditions for which it was not prescribed. <span class="Bold">Do not</span> give POMALYST to other people, even if they have the same symptoms you have. It may harm them and may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>.</p>
<p>If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about POMALYST that is written for health professionals.</p>
<p>For more information, call 1-888-423-5436 or go to <span class="Underline">www.CelgeneRiskManagement.com</span>.<br><br></p>
<p><span class="Bold">What are the ingredients in POMALYST?</span></p>
<p><span class="Bold">Active ingredient:</span> pomalidomide<br><span class="Bold">Inactive ingredients:</span> mannitol, pregelatinized starch, and sodium stearyl fumarate.</p>
<p>The 1-mg capsule shell contains gelatin, titanium dioxide, FD&amp;C blue 2, yellow iron oxide, white ink, and black ink.<br>
							The 2-mg capsule shell contains gelatin, titanium dioxide, FD&amp;C blue 2, yellow iron oxide, FD&amp;C red 3, and white ink.<br> 
							The 3-mg capsule shell contains gelatin, titanium dioxide, FD&amp;C blue 2, yellow iron oxide, and white ink.<br>  
							The 4-mg capsule shell contains gelatin, titanium dioxide, FD&amp;C blue 1, FD&amp;C blue 2, and white ink.
						</p>
<br><p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured for: Celgene Corporation, Summit, NJ 07901</p>
<p>Revised: April 2015</p>
<p>POMALYST<span class="Sup">Â®</span>, REVLIMID<span class="Sup">Â®</span>, THALOMID<span class="Sup">Â®</span> and POMALYST REMS<span class="Sup">Â®</span> are registered trademarks of Celgene Corporation.
							<br>Pat. http://www.celgene.com/therapies</p>
<p>Â© 2005-2015 Celgene CorporationÂ Â Â All rights reserved.</p>
<p>POMMG.004 04/2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SB190"></a><a name="section-18"></a><p></p>
<h1>Pomalyst<span class="Sup">Â®</span> (pomalidomide) Capsules, 1 mg - 21 Count Bottle Label</h1>
<p class="First"><img alt="Pomalyst (pomalidomide) Capsules, 1 mg - 21 Count Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66&amp;name=pom-figure-2.jpg"></p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SB191"></a><a name="section-19"></a><p></p>
<h1>Pomalyst<span class="Sup">Â®</span> (pomalidomide) Capsules, 1 mg - 100 Count Bottle Label</h1>
<p class="First"><img alt="Pomalyst (pomalidomide) Capsules, 1 mg - 100 Count Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66&amp;name=pom-figure-3.jpg"></p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SB192"></a><a name="section-20"></a><p></p>
<h1>Pomalyst<span class="Sup">Â®</span> (pomalidomide) Capsules, 2 mg - 21 Count Bottle Label</h1>
<p class="First"><img alt="Pomalyst (pomalidomide) Capsules, 2 mg - 21 Count Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66&amp;name=pom-figure-4.jpg"></p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SB193"></a><a name="section-21"></a><p></p>
<h1>Pomalyst<span class="Sup">Â®</span> (pomalidomide) Capsules, 2 mg - 100 Count Bottle Label</h1>
<p class="First"><img alt="Pomalyst (pomalidomide) Capsules, 2 mg - 100 Count Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66&amp;name=pom-figure-5.jpg"></p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SB194"></a><a name="section-22"></a><p></p>
<h1>Pomalyst<span class="Sup">Â®</span> (pomalidomide) Capsules, 3 mg - 21 Count Bottle Label</h1>
<p class="First"><img alt="Pomalyst (pomalidomide) Capsules, 3 mg - 21 Count Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66&amp;name=pom-figure-6.jpg"></p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SB195"></a><a name="section-23"></a><p></p>
<h1>Pomalyst<span class="Sup">Â®</span> (pomalidomide) Capsules, 3 mg - 100 Count Bottle Label</h1>
<p class="First"><img alt="Pomalyst (pomalidomide) Capsules, 3 mg - 100 Count Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66&amp;name=pom-figure-7.jpg"></p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SB196"></a><a name="section-24"></a><p></p>
<h1>Pomalyst<span class="Sup">Â®</span> (pomalidomide) Capsules, 4 mg - 21 Count Bottle Label</h1>
<p class="First"><img alt="Pomalyst (pomalidomide) Capsules, 4 mg - 21 Count Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66&amp;name=pom-figure-8.jpg"></p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SB197"></a><a name="section-25"></a><p></p>
<h1>Pomalyst<span class="Sup">Â®</span> (pomalidomide) Capsules, 4 mg - 100 Count Bottle Label</h1>
<p class="First"><img alt="Pomalyst (pomalidomide) Capsules, 4 mg - 100 Count Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66&amp;name=pom-figure-9.jpg"></p>
<br><br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>POMALYSTÂ 		
					</strong><br><span class="contentTableReg">pomalidomide capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59572-501</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POMALIDOMIDE</strong> (POMALIDOMIDE) </td>
<td class="formItem">POMALIDOMIDE</td>
<td class="formItem">1Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STEARYL FUMARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW,Â BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">POML;1;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59572-501-21</td>
<td class="formItem">21  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:59572-501-00</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204026</td>
<td class="formItem">02/18/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>POMALYSTÂ 		
					</strong><br><span class="contentTableReg">pomalidomide capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59572-502</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POMALIDOMIDE</strong> (POMALIDOMIDE) </td>
<td class="formItem">POMALIDOMIDE</td>
<td class="formItem">2Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STEARYL FUMARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE,Â BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">POML;2;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59572-502-21</td>
<td class="formItem">21  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:59572-502-00</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204026</td>
<td class="formItem">02/18/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>POMALYSTÂ 		
					</strong><br><span class="contentTableReg">pomalidomide capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59572-503</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POMALIDOMIDE</strong> (POMALIDOMIDE) </td>
<td class="formItem">POMALIDOMIDE</td>
<td class="formItem">3Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STEARYL FUMARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN,Â BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">POML;3;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59572-503-21</td>
<td class="formItem">21  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:59572-503-00</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204026</td>
<td class="formItem">02/18/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>POMALYSTÂ 		
					</strong><br><span class="contentTableReg">pomalidomide capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59572-504</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POMALIDOMIDE</strong> (POMALIDOMIDE) </td>
<td class="formItem">POMALIDOMIDE</td>
<td class="formItem">4Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STEARYL FUMARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE,Â BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">POML;4;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59572-504-21</td>
<td class="formItem">21  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:59572-504-00</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204026</td>
<td class="formItem">02/18/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Celgene Corporation
							(174201137)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>24e9ecda-09f0-4c56-9c6f-0c67236a5e36</div>
<div>Set id: 2b25ef01-5c9e-11e1-b86c-0800200c9a66</div>
<div>Version: 7</div>
<div>Effective Time: 20150430</div>
</div>
</div>Â <div class="DistributorName">Celgene Corporation</div></p>
</body></html>
